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1.1   Definition, incidence and symptoms  
of Pheochromocytoma and Paraganglioma
Pheochromocytoma and paraganglioma (PPGL) are neuroendocrine tumours of 
neural crest derived cells. As per the recommendation of the World Health 
Organization, the term pheochromocytoma refers to tumours of sympathetic tissue 
of adrenal medulla while all other tumours of sympathetic and parasympathetic 
nervous tissue are called sympathetic and parasympathetic paragangliomas 
(PGLs), respectively (1). They arise in chromaffin cells of adrenal medulla and 
extra-adrenal sympathetic and parasympathetic paraganglia. Paraganglia are 
small organs that mainly consist of neuroendocrine cells derived from embryonic 
neural crest that have the ability to synthesize and secrete catecholamines (2). 
In this thesis, pheochromocytoma and sympathetic paraganglioma together, are 
referred to as PPGLs. PPGLs are further classified by their site viz., pelvis, abdominal 
and thorax. PPGLs secrete excessive amounts of catecholamines while the para-
sympathetic head and neck paragangliomas (HNPGLs) usually do not secrete 
clinically relevant amounts of catecholamines (1,3). 
 In Western countries, the prevalence of (a history of) PPGL can be estimated at 
between 1:4500 and 1:1700, with an annual incidence of 3 to 8 cases per 1 million 
per year in the general population. Undiagnosed lesions account for approximately 
5% of adrenal incidentalomas. Clinical symptoms of sympathetic PPGLs are 
mostly due to excessive catecholamine concentrations in circulation. Symptoms 
can include paroxysmal episodes of headaches, palpitation and sweating. 
Additionally pallor, panic/anxiety, fever and nausea might also be seen (1). Most 
of these PPGLs are benign, however, 10% of pheochromocytomas and 15-35% of 
paragangliomas show malignancy. Traditionally, malignancy in PPGLs is defined 
by the presence of metastases of chromaffin tissue in organs like lung, liver, bone 
and lymph nodes. Prognosis of malignancy in PPGLs is highly variable with a 
mean 5 year survival rate of 50% (4,5). The outcome worsens with tumour size, 
organ of metastases and the SDHB genotype (6). Tumours caused by mutations in 
SDHB and MAX are particularly at high risk for metastases (7). PPGLs are diagnosed 
by the excessive secretion of catecholamines. Detection of excessive secretion of 
plasma free metanephrines and urinary excretion of metanephrines are 
considered the gold standard test. Following biochemical diagnosis, tumour is 
localized using various imaging methods (8) (see paragraph 1.5).
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1.2  Genetic background of PPGLs
Nearly 40% of PPGLs are due to hereditary mutations in at least 13 tumour 
susceptibility genes.  These include genes which when mutated result in familial 
syndromes with autosomal dominant inheritance namely, RET causing Multiple 
Endocrine Neoplasia type 2A and 2B, VHL causing von Hippel Lindau disease and 
NF1 causing Neurofibromatosis type 1, all of which mainly present pheochromo-
cytomas. Hereditary mutations in fumarate hydratase (FH) gene result in hereditary 
leiomyomatosis and renal cell cancer and in exceptional cases in paragangliomas 
(7). Most recently, mutations in the gene for malate dehydrogenase type 2 (MDH2) 
have been associated with PPGL (9).Genes in which mutations result in familial 
and non-syndromic presentation include genes encoding succinate dehydrogenase 
subunits, SDHA, SDHB, SDHC and SDHD and assembly factor SDHAF-2. SDHx-related 
PPGL are autosomal dominant disorders with usually a high penetrance. Mutations 
in the tumour suppressor genes TMEM127 and MAX lead to familial pheochromo-
cytomas and mutations in the oncogene EPAS1 lead to PPGLs, polycythemia and/
or somatostatinoma in patients depending on the degree of mosaicism and the 
organ affected (7). A summary of the hereditary mutations leading to PPGLs and 
associated conditions is provided in table 1.
 Tumours which are not associated with hereditary mutations in any of the 
known tumour susceptibility genes are known as sporadic tumours. Presence 
of somatic mutations in RET, NF1, VHL, EPAS1 and HRAS have been reported to 
cause PPGLs. About 20% of sporadic PPGLs have somatic mutations in NF-1, 14% 
have mutations in NF1 and VHL and about 5% in HRAS (10-13). Recently, somatic 
mutations in HRAS, BRAF and TP53 were also identified to occur in PPGLs and 
it was suggested that HRAS/BRAF mutations could be mutually exclusive (14). 
 It is also important to recognize that even though primary hereditary 
mutations are present which could lead to cancer, cooperative somatic events are 
required for initiation and progression of cancer. Studies have also revealed that 
there is intra- and inter-tumour genetic heterogeneity in tumours from the same 
patient. Patients with distant metastases showed greater intra-tumour heterogeneity, 
while local recurrences with metastatic invasion were more closely related to the 
primary tumour and exhibited a low degree of intra-tumour heterogeneity (12). 
As PPGLs can arise due to hereditary mutations in a large number of genes, studying 
these tumours can also have implications on other cancers which share the patho-
physiology in terms of mechanisms that lead to tumour formation.
11
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1.3   Pathophysiology in relation to genetic  
background of PPGLs
PPGLs can be classified into two clusters based on transcription profiling data. 
Cluster 1 includes SDHx- and VHL-related tumours. This cluster is characterized by 
expression of genes involved in hypoxic response. Two recently identified genes 
associated with PPGLs, FH and EPAS-1, are also classified along with this cluster 
Table 1  Hereditary mutations associated with PPGLs and related disorders*
Disease Genes % with 
PPGL
Main features
Neurofibromatosis 
type 1
NF1 3 Café-au-lait spots, neurofibromas, axillary 
and inguinal freckling, Lisch nodules, 
osseous lesions, optic gliomas, mainly 
pheochromocytomas
Multiple endocrine 
neoplasia type 2
RET 6 2A: Medullary thyroid cancer, primary 
hyperparathyroidism, PPGL
2B: Medullary thyroid cancer, PPGL, 
Marfanoid habitus, mucocutaneous 
neuromas, gastrointestinal 
ganglioneuromatosis
von Hippel–Lindau 
disease
VHL 7 Central nervous system or retinal 
haemangioblastomas, renal cell carcinoma, 
PPGL, pancreatic neuroendocrine tumours 
and cysts, endolymphatic sac tumours, 
papillary cystadenoma of the epididymis 
and broad ligament
Hereditary 
paragangliomas
SDHB
SDHD
SDHC
SDHA
SDHAF2
10
9
1
<1
<0.1
PPGL, rare renal cancers, GIST
PPGL, rare renal cancers, GIST
PPGL, rare renal cancers, GIST
PPGL, GIST
Head and neck paraganglioma
Familial 
pheochromocytomas
TMEM127
MAX
1
1
Mainly pheochromocytomas, rare renal 
cancers
Mainly PPGL
Polycythemia 
paraganglioma 
syndrome
EPAS1 1 Polycythemia, PPGL, somatostatinoma
Leiomyomatosis  
and renal cell cancer
FH 1 Cutaneous and uterine leiomyomas, type 2 
papillary renal carcinoma, rare PPGL
* adapted from Favier et al., 2015 (7)
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though originally when the first transcriptomic studies were published they were 
not known to be associated with the disease. Cluster 2 includes tumours with 
mutations in RET and NF-1. Most of the sporadic tumours also belong to this 
category. These tumours show increased activation of the MAPK and PI3K/AKT 
pathways. TMEM127 and MAX tumours also are identified with cluster 2 (7,15,16). 
Although, the two clusters seem to activate distinct signalling pathways, they are 
interconnected in activation of HIF signalling as major driver of tumourigenesis (17).  
 In cluster 1 tumours, HIF-1α and -2α are stabilized either due to accumulation 
of succinate inhibiting the enzyme prolyl hydroxylase needed for proteolytic 
degradation of HIF or due to dysfunctional proteosomal HIF degradation complex 
due to mutation in VHL which is a component of this complex. In both cases, 
HIF-1α and -2α translocate to the nucleus where, together with the aryl hydrocarbon 
receptor nuclear translocator, they form an active HIF complex that induces the 
expression of genes with hypoxia response elements supporting tumour 
progression. This ‘pseudohypoxic response’ leads to elevated expression of genes 
involved in glycolysis and angiogenesis. Thus, in cluster 1 tumours, the pseudo -
hypoxic drive is hypothesized to mediate an increase in aerobic glycolysis, also 
known as Warburg effect (18,19).
 In RET and NF-1 related cluster 2 tumours, HIF activation is driven through 
activation of Ras/Raf/MAPK pathway. Ras activation results in the activation of 
downstream PI3K, MAPK and mTORC pathways. Activation of extracellular signal- 
 regulated kinase (ERK), a component of Ras/MAPK pathway leads to  phosphorylation 
of HIF-1α while downstream target of PI3K, nuclear factor kappa B (NF-ϰB) is also 
known to activate HIF- α pathway. In TMEM127 and MAX related tumours, HIF- α 
levels are related to mTORC activation (17). A summary of how pathophysiology 
of cluster 1 and cluster 2 tumours are interrelated through activation of HIF is 
depicted below in Figure 1. 
1.4   Alterations in metabolism in relation to  
genetic background
Genotype-specific differences have been reported in catecholamine metabolism 
in PPGLs. Catecholamines are the hormones and neurotransmitters of adreno-
medullary, sympathoneuronal and brain catecholaminergic systems. Catecholamines 
bind to α (α1 and α2) and β (β1, β2 and β3) adrenergic receptors in target cells and 
eliciting either activation or inhibition of target cells. Physiological effects of 
catecholamines include increasing the activity of heart muscles, blood vessels, 
increasing basal metabolic rate, glucose levels and lipolysis. 
13
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The catecholamine biosynthetic pathway is depicted in Figure 1. Catecholamines 
are synthesized from the precursor amino acid L-tyrosine. Tyrosine is obtained 
through diet as well as conversion of phenylalanine to tyrosine in liver. Tyrosine 
is converted to L-dihydroxyphenylalanine (L-DOPA) by the enzyme tyrosine 
hydroxylase in adrenal chromaffin cells, sympathetic and brain catecholaminergic 
nerve terminals. L-DOPA is converted to dopamine by a non-specific enzyme 
L- amino acid decarboxylase (AAD). Dopamine is taken up from the storage 
vesicles where the enzyme dopamine-β-hydroxylase (DBH) converts dopamine to 
Figure 1  Hypoxia inducible factor (HIF) signaling in cluster 1 and cluster 2. Yellow marks 
highlight the tumour susceptibility genes linked to HIF activation. Adapted from Jochmonova 
et al., 2013 (17).
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norepinehrine. Norepinephrine is released into the cytosol by exocytosis where 
cytoplasmic enzyme phenylethanolamine-N-methyl transferase (PNMT) converts 
norepinephrine to epinephrine. PNMT is mainly present in adrenal medulla and 
certain population of chromaffin cells contain PNMT and consequently separate 
populations contain epinephrine and norepinephrine as their end products 
(Kvetnansky et al., 2009). Once released, catecholamines are further metabolized 
or are taken back up into sympathetic nerve endings/chromaffin cells and/or to 
effector cells. This uptake is mediated by norepinephrine transporter (NET). NET 
helps in reuptake of norepinephrine and dopamine and has low affinity to 
epinephrine in neuronal tissue. In extraneuronal tissue, epinephrine is favourably 
Figure 2 Pathway for catecholamine biosynthesis and its enzymatic steps. The steps of 
conversion from L-tyrosine to L-noradrenaline are typical for sympathetic and some brain 
neurons, and the conversion of L-norepinephrine to L-epinephrine is typical for the adrenal 
medullary cells and some peripheral and brain neurons. Adapted from Kvetnansky et al., 
2009 (20).
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taken up over norepinephrine. Reuptake is dependent on Na+/Cl- gradient in 
neuronal tissue while in extraneuronal chromaffin cells, it is independent of the 
gradient. It is to be noted that maintenance of Na+/Cl- gradient is an energy 
dependent process.
 Vesicular monoamine transporters (VMATs) help in sequestration of catecho-
lamines from cytoplasm into chromaffin granules and sympathetic synaptic vesicles. 
VMAT has two isoforms, VMAT1 and VMAT2. Sympathetic nerves in periphery or 
brain express VMAT2 while adrenal medullary chromaffin cells express both 
VMAT1 and 2 (VMAT2 major isoform in humans). The vesicular uptake requires 
energy which is provided by the proton gradient established by ATP-dependent 
H+ pump. VMAT is sensitive to the pH gradient and the membrane potential (20). 
 
Tumours of different genotypes are characterized by differences in catecholamine 
biosynthetic and secretory profiles. In contrast to patients with VHL- and 
SDH-related tumours, PPGLs with mutations in RET and NF1 present with tumours 
characterized by increased plasma metanephrine concentrations indicative of 
increased epinephrine production. On the other hand, PPGLs with mutations in 
VHL showed increased production of norepinephrine as evidenced by increased 
plasma normetanephrine levels (21). Patients with SDHB- and SDHD-related 
tumours showed increased plasma levels of methoxytyramine indicative of 
increased dopamine production. However, overall tumour catecholamine content 
is lower in cluster 1 tumours, compared to cluster 2 tumours. In addition, RET- and 
NF1-related PPGLs and sporadic tumours with similar secretory profiles showed a 
lower rate of catecholamine secretion than VHL-, SDH-related and norepinephrine 
secreting sporadic tumours which did not have high epinephrine content (22).
 Other aspects of metabolism altered in a genotype-specific way include 
oxidative phosphorylation and glycolysis. Mitochondrial oxidative phosphorylation 
plays a pivotal role in cellular energy production through activity of respiratory 
chain enzyme complexes. Of the four respiratory chain enzyme complexes 
(complex I-IV), complex II or succinate dehydrogenase has a unique role as it is 
an important component of the respiratory chain as well as the Krebs cycle. 
The mitochondrial succinate dehydrogenase (SDH) complex catalyzes the 
oxidation of succinate to fumarate in the Krebs cycle, and feeds electrons to the 
respiratory chain ubiquinone pool. It consists of four nuclear encoded subunits A, 
B, C and D. The SDHA subunit contains the covalently attached flavin adenine 
dinucleotide (FAD) cofactor and the succinate binding site. SDHB subunit contains 
the iron-sulphur clusters and SDHC and D subunits are involved in membrane 
anchoring and electron transfer to ubiquinone. Thus, mutation in any of the SDH 
subunits is expected to impair the enzyme activity leading to succinate 
accumulation as well as electron transfer function.  As explained in section 1.3, 
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consistent with the hypothesis of activation of pseudohypoxic response, increased 
levels of HIF-2α are observed in SDH- and VHL-related tumours when compared to 
cluster 2 tumours (16,23). Increased HIFα levels and nuclear translocation leads to 
increased expression of a wide variety of genes involved in angiogenesis, glycolysis, 
invasion and metastasis. Increased vascular density as evidenced by increased 
CD34 staining is observed in SDH- and VHL- related tumours. VHL-related tumours 
also exhibit increased lactate dehydrogenase activity (16). However, the impact of 
genotype on tumour metabolism in PPGLs had not been systematically studied 
before the studies that comprise this thesis were initiated.
1.5  Role of metabolism in imaging of PPGLs
Various functional imaging modalities are used in localization of PPGLs. These 
functional imaging contrast agents target catecholamine metabolism (synthesis, 
storage and secretion) or energy metabolism (glycolysis). 123/131I-metaiodobenzyl-
guanidine (123/131I-MIBG) scintigraphy and 18F- fluorodopamine positron emission 
tomography (18F-FDA PET) target the norepinephrine transporter of the PPGL cell 
membrane and the vesicular monoamine transporters in the membrane of 
intra cellular vesicles. These transporters facilitate the re-uptake and storage of 
catecholamines, respectively. Thus, they are effective in detecting RET- and 
NF-1-related tumours (24).
 On the other hand, 18F- fluorodeoxy glucose (18F-FDG)-PET has high sensitivity 
and specificity in detecting VHL- and SDH-related tumours including metastatic 
lesions (24,25). The avidity of cluster 1 tumours in uptake of 18F-FDG is hypothesized 
to be reflective of increased glycolysis which is related to the pseudohypoxic drive 
in these tumours. The relationship between tumour energy metabolism and 
functional imaging characteristics is the topic of investigation in this thesis. The 
findings hold promise to improve the imaging tools used for tumour localization.
1.6  Aims and scope of the thesis
The aim of this thesis is to study the impact of genotype-specific alterations in 
tumour energy metabolism in PPGLs on diagnostic characteristics and metastatic 
potential. For this purpose, targeted and untargeted ex-vivo metabolomic 
investigations of PPGL tumour tissues are compared with clinical characteristics 
and in vivo functional imaging of patients.  In chapter 1, we describe the impact of 
genotype specific alterations in respiratory chain enzyme activities on energy 
and catecholamine metabolism in PPGLs. For this purpose, we use respiratory 
17
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chain enzyme assays to assess the respiratory chain activity and proton nuclear 
magnetic resonance (1H NMR) spectroscopy to analyze metabolite levels.
 In chapter 2, we further extend the study described in chapter 1 to understand 
the genotype-specific differences in the PPGL metabolic profile. Towards this end, 
untargeted and targeted metabolic profiling is carried out using 1H NMR 
spectroscopy and HPLC tandem mass spectrometry. We investigate the link 
between altered energy metabolism and purine and amino acid metabolism.
In chapter 3, we investigate gene expression changes that could help PPGLs to 
cope with prolonged pseudohypoxia. Early hypoxic response leads to activation of 
p53 through HIF-1α mediated stabilization. However, in PPGLs, loss of p53 is 
associated with sustained pseudohypoxia (16). Here we investigate the role of 
antisense HIF, which encodes the antisense template of the 3’-untranslated region 
of HIF-1α mRNA and inhibits the translation of HIF-1α mRNA after chronic 
hypoxia. 
 In chapter 4, we investigate how the genotype-specific differences in PPGL 
energy metabolism are related to increased 18F-FDG uptake observed in-vivo in 
PPGLs of various genotypes. 
 In chapter 5, the findings presented in this thesis, future perspectives for 
application of findings and further research questions that could be addressed are 
discussed. Chapter 6 presents a summary of the findings of the research work of 
this thesis.
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Abstract
Purpose: Pheochromocytomas and paragangliomas (PGLs) are neuroendocrine 
tumours of sympathetic and parasympathetic paraganglia. The present study 
investigated the relationships between genotype-specific differences in 
mitochondrial function and catecholamine content in PGL tumours. 
Experimental Design: Respiratory chain enzyme assays and 1H-NMR spectroscopy 
at 500 MHz, were performed on homogenates of 35 sporadic PGLs and 59 PGLs 
from patients with hereditary mutations in SDHB, SDHD, SDHAF-2, VHL, RET, NF1 
and MAX. 
Results: In SDHx related PGLs, a significant decrease in complex II activity 
(p<0.0001) and a significant increase in complex I, III and IV enzyme activities 
were observed when compared to sporadic, RET and NF1 tumours. Also, a 
significant increase in citrate synthase (p<0.0001) enzyme activity was observed 
in SDHx related PGLs when compared to sporadic, VHL, RET and NF1 related ones. 
An increase in succinate accumulation (p<0.001) and decrease in ATP/ADP/AMP 
accumulation (p<0.001) was observed when compared to sporadic PGLs and PGLs 
of other genotypes. Positive correlations (p<0.01) were observed between 
respiratory chain complex II activity and total catecholamine content and ATP/
ADP/AMP and total catecholamine contents in tumour tissues. 
Conclusions: The present study for the first time establishes relationship between 
determinants of energy metabolism like activity of respiratory chain enzyme 
complex II, ATP/ADP/AMP content and catecholamine content in PGL tumours. 
Also, the present study for the first time successfully uses NMR spectroscopy to 
detect catecholamines in PGL tumours and provides ex vivo evidence for the 
accumulation of succinate in PGL tumours with a SDHx mutation.
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2.1  Introduction
Pheochromocytomas and paragangliomas are neuroendocrine tumours of 
sympathetic (PGLs) and parasympathetic paraganglia. PGLs of sympathetic origin 
(adrenal medulla and extra adrenal sympathetic tissue of abdomen, pelvis and 
chest) usually produce catecholamines whereas the tumours of parasym pathetic 
origin (head and neck PGLs (HNPGLs)) usually do not produce significant amounts 
of catecholamines (1). At least 30%-35% of the PGLs are caused by germline 
mutations of ten identified tumour susceptibility genes (2). These include VHL 
(von Hippel-Lindau), RET (rearranged during transfection), NF1 (neuro fibromatosis 
type 1), SDHA/B/C/D (succinate dehydrogenase subunits A, B, C and D), SDHAF2 
(succinate dehydrogenase assembly factor 2) and the more recently reported 
TMEM127 (transmembrane protein 127) and MAX (myc-associated factor X) (2). 
In 17% of sporadic tumours, somatic mutations in RET, VHL, MAX and more 
recently, HIF-2α and NF1 have been reported (3-5).
 Based on transcriptional profiling studies, PGLs can be classified into two 
clusters: cluster 1 and cluster 2 (6, 7). Cluster 1 tumours (VHL, SDHA/B/C/D/AF2) are 
characterized by increased expression of genes involved in (pseudo)hypoxia, cell 
proliferation, angiogenesis, electron transport chain and the Krebs cycle and 
abnormal function of oxidoreductases. Cluster 2 tumours (RET, NF1) show an 
increased expression of genes involved in protein synthesis, kinase signaling, 
endocytosis and maintenance of a differentiated chomaffin cell catecholamine 
biosynthetic and secretory phenotype. Sporadic PGLs are distributed between the 
two major clusters based on their gene expression pattern and catecholamine 
phenotype (6).  
 SDH is an important component of the mitochondrial electron transport 
chain. In tumours with SDHx mutations, the ability of cells for oxidative phos-
phorylation is compromised (7-10). Also, it has been demonstrated in vitro that 
accumulation of succinate in cells silenced for SDH causes inhibition of prolyl 
hydroxylase activity resulting in stabilization of hypoxia-inducible factors (HIF) 
-1α and -2α (11, 12). HIF-1α and -2α then translocate to the nucleus where, together 
with aryl hydrocarbon receptor nuclear translocator (ARNT), they form an active 
HIF complex that induces the expression of genes with hypoxia response elements 
that support tumour progression via different signaling pathways. Thus, in 
cluster 1 tumours, the pseudo-hypoxic drive is hypothesized to mediate an 
increase in aerobic glycolysis, also known as Warburg effect. This is supported by 
increased HIF-α protein level combined with lower SDH activity and increased 
glycolysis as indicated by lactate dehydrogenase activity (7).
 The differences between cluster 1 and 2 tumours are also characterized by 
differences in catecholamine biosynthetic and secretory profiles (13). PGLs with 
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mutations in RET and NF1 produce both epinephrine and norepinephrine and 
have low rate constants for catecholamine secretion, whereas SDHx and VHL–
related tumours mainly produce norepinephrine and have high rate constants for 
catecholamine secretion. Tumour catecholamine content is lower in cluster 1 
tumours, compared to cluster 2 tumours. Also, it is well known that sequestration of 
catecholamines into chromaffin granules through vesicular monoamine transporters 
(VMAT) and re-uptake of catecholamines via norepinephrine transporter (NET) 
are active energy dependent processes. Differences in catecholamine phenotypes 
may thus in part be explained by mutation-dependent changes in energy 
metabolism. 
 In the present study, we therefore investigated relationships between geno-
type-specific differences in mitochondrial function and catecholamine content in 
PGL tumours. Ninety PGL tissues of various genotypes were included. Besides 
functional assays for respiratory complex I-IV and citrate synthase (CS), 1H nuclear 
magnetic resonance (NMR) spectroscopy was performed to provide an overview 
of the intracellular metabolome with specific focus on catecholamines, AMP/
ADP/ATP and intermediates of glycolysis and Krebs cycle.
2.2  Materials and methods
Patients 
Patients with histologically proven PGLs evaluated at the department of General 
Internal Medicine, division of Endocrinology of the Radboud University Nijmegen 
Medical Centre (RUNMC), Nijmegen, the Netherlands and at Eunice Kennedy 
Shriver National Institute of Child Health and Human Development (NICHD), 
National Institute of Health (NIH), Bethesda, MD, USA were considered for the 
study. Tumour tissue samples of consecutive patients from RUNMC who 
underwent surgical resection between 1988 and 2012 were included in the study. 
NIH patients underwent surgery between 2003 and 2010. Frozen primary tumour 
tissues from 64 patients at RUNMC and 26 patients at NICHD were included. The 
presence of germline mutations and large deletions in SDHB/C/D, RET, VHL and 
-since 2011- in SDHA, SDHAF2, TMEM127 and MAX, was investigated using standard 
procedures. Data were collected under conditions of regular clinical care, with 
ethical committee approval obtained for the use of those data for scientific 
purposes at RUNMC. The study was approved by the Institutional Review Board of 
NICHD, and all patients gave written informed consent before testing. The details 
of the patients’ clinical characteristics and genotype are listed in Table 1.
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Tumour tissue processing 
Tumour tissues resected from the patients described above were procured as early 
as possible, the dimensions of the tumour were recorded by the pathologist and a 
small piece of the tumour tissue was weighed and snap frozen and stored in liquid 
Nitrogen and later used for experimental purposes. For histological confirmation, 
additional slices were stained with hematoxylin and eosin and re-evaluated by 
an independent pathologist (BK).
Respiratory chain enzyme assays 
Frozen tumour specimens (~40 mg) were homogenized on melting ice in sucrose- 
EDTA-phosphate buffer (0.25 M sucrose, 2 mM EDTA, 10 mM K2PO4, pH 7.4, 8% w/v) 
using a hand held glass/glass homogenizer. Homogenates were subsequently 
centrifuged at 600xg at 4oC for 10 min and supernatants used for the determination 
of the activities of respiratory chain enzyme complexes I, II, III and IV and the 
mitochondrial matrix enzyme, CS. These assays measured the formation of a 
spectrophotometrically detectable end-product at regular time intervals and 
were performed on Konelab 20XT clinical chemistry analyzer (Thermo Scientific, 
Finland) as described elsewhere (14). The protein concentrations in the super- 
natants were also measured in parallel using pyrogallol red-molybdate complex 
method as described earlier (15). The enzyme activities were normalized to mg 
protein. Five samples were excluded from analysis (Sporadic- 2, SDHB, VHL and 
NF1- 1 each) as the tumour tissue homogenate contained blood which could affect 
determinations and interpretations of respiratory chain enzyme activities and 
protein concentrations. 
Table 1  Patient Characteristics
Genotype N (patients) Age
y (mean±SD)
Gender 
(M/F)
N 
(tumours)
Tumour 
Location 
(A/E/HN)
Tumour volume 
(cm3)
Sporadic 35 47.5 ± 14.8 18/17 35 32/3/0 218.6 ± 452.5
SDHB 13 32 ± 11.9 10/3 15 1/14/0 273.1 ± 316.2
SDHD 8 44 ± 10.4 6/2 8 1/1/6 27.9 ± 47
SDHAF2 1 24 1/0 1 0/0/1 18.9
VHL 9 30.7 ± 13 6/3 9 7/2/0 61.5 ± 84.9
MEN-2 13 37.9 ± 12.8 6/7 15 15/0/0 93.4 ± 171.6
NF1 8 43.2 ± 17.4 5/3 8 8/0/0 107.6 ± 80.6
MAX 3 48 ± 14 2/1 3 3/0/0 63.2 ± 71.9
N: No. of patients, y: years, M: Male, F: Female, A: Adrenal, E: Extraadrenal, HN: head and neck
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1H NMR Spectroscopy 
1H NMR spectroscopy was performed in frozen tumour tissues to determine 
concentrations of intermediates of energy metabolism (Krebs cycle and glycolysis), 
catecholamines and their metabolites. One sporadic, 2 SDHB, 1 VHL and 2 MAX 
tumours were excluded from the experiment as the amount of starting material 
was low. The tumour tissues were homogenized on ice in 10% w/v of distilled 
water using a hand held Teflon/glass homogenizer. The samples were then 
centrifuged at 16,000xg for 10 min at 4oC and the supernatants were subjected to 
ultrafiltration with Vivaspin Turbo 15, 10 kDa filters (Sartorius, Germany). The 
ultrafiltrates were diluted with water to 700 µl, pH was adjusted to 2.5 and 20 µl of 
20.2 mM sodium 3-trimethylsilyl-2,2,3,3-tetradeuteropropionate (TSP) in D2O was 
added to the samples. The samples were then placed in 5 mm NMR tubes and 1H 
NMR spectra were obtained using a Bruker 500 MHz spectrometer (pulse angle 
90o, 7 µs pulses with a delay time of 4 s, number of scans 256). The water resonance 
was suppressed by gated irradiation centered on water frequency (16, 17).
 Concentrations of succinate in the tumour tissues were estimated by 
integrating the area under the peak at 2.66 ppm. Differences in peak heights were 
clearly observed for tumours with high, absent and low levels of succinate 
(Supplementary Figure 1). Tumour tissue ATP/ADP/AMP content were estimated 
by integrating the area under peaks in the region 6.18-6.21 ppm. Since each of the 
three compounds differ by the presence of one phosphate group, spectral peaks 
for these metabolites cannot be distinguished using 1H NMR spectroscopy. 
Epinephrine content was estimated by integrating area under the peaks for the 
triplet at 2.73 ppm and the total catecholamine content was estimated by 
integrating the area under the peaks for multiplets in the region 6.86-6.98 ppm 
(Supplementary Figure 1). Further, norepinephrine content was estimated by 
calculating the difference between total catecholamine and epinephrine 
contents. Other amines, which could contribute to peaks in the region 6.86-6.98 
ppm are dopamine and 3-methoxytyramine. However, the concentration of these 
compounds as measured by HPLC is in the nanomolar range (18), much lower than 
the detection limit of 1H NMR spectroscopy, which is in micromolar range. The 
catecholamine content of the tumour tissue as estimated by 1H NMR spectroscopy 
was validated in a small subset of 22 samples using HPLC. For this purpose, the 
frozen tumour tissues (~5 mg) were weighed accurately, transferred to a processing 
tube and 5 volumes of 0.4 M perchloric acid containing 0.5 mM EDTA is added and 
homogenized on ice using a homogenizer (Polytron). The tubes are then spun for 
15 minutes at 3000 rpm in a refrigerated centrifuge to separate the precipitated 
proteins and cell debris. The perchloric acid extract is separated from the pellet, 
frozen on dry ice and stored at -800C until assayed for catecholamines.  Further, 
the perchloric acid extract is prepared using alumina extraction method as 
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described previously (19). A significant correlation and linear relationship was 
observed between the two methods (Supplementary Figure 2). 
Statistical Methods  
Statistical analyses were performed using SPSS (SPSS Inc., v.18) and GraphPad 
Prism 6 software (GraphPad, La Jolla, CA). The data was analyzed using independent 
samples Kruskal-Wallis test and Dunn’s post-test was used to compare the 
different genotypes and adjusted P values were reported. Correlation between 
respiratory chain enzyme activities and tumour tissue catecholamine content 
was examined using Spearman’s correlation test. Statistical significance was 
accepted at P value <0.05. Further, estimation of catecholamine content by 1H 
NMR spectroscopy and HPLC and comparison of respiratory chain enzyme 
activities with total catecholamine content was carried out using Passing-Bablok 
regression analysis (20). 
2.3 Results
Respiratory chain enzyme activities 
The activity of the respiratory chain complex II was deficient in all SDHx tumours 
as expected (Fig 1B; p<0.0001). The activity of the complexes I, III and IV was 
significantly higher in SDHx tumours than in VHL, RET, NF1 and sporadic tumours 
(Fig 1A, C, D, p<0.05). This was even more clearly so for citrate synthase activity 
(Fig 1E; p<0.0001). The VHL tumours showed a lower activity for Complex I when 
compared to sporadic tumours (Fig 1A, Table 2, p<0.05) and complex III when 
compared to sporadic (Fig 1C, Table 2, p<0.01) and cluster II tumours (Fig 1C, Table 2, 
p<0.05). In contrast, the MAX tumour group had a tendency of higher activity for 
the complexes II, III and IV when compared to the other genotypes (Fig 1B-D). 
Further, for the various SDH mutations no mutation specific differences could be 
observed in the activities of respiratory chain enzyme complexes I-IV. Although a 
low complex II activity was observed in SDHB related tumours when compared to 
SDHD related ones, the sensitivity of the assay at such low enzyme activity levels 
precludes such an analysis and interpretation of the results (supplementary 
figure 3).
Detection of energy metabolism intermediates and tumour tissue 
catecholamines using 1H-NMR spectroscopy 
The NMR spectra of the tumour homogenates showed very high succinate 
(p<0.001) levels in all SDHx cases as expected (Fig 2A). Mutation specific differences 
in the levels of succinate could not be observed for the tumours with various SDH 
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mutations (supplementary figure 3). Succinate was not NMR detectable or very 
low in all other tumour samples except for 1 tumour in the sporadic group. Citrate 
was present in high concentration in four sporadic tumours. Low concentrations 
of pyruvate, without genotype specific differences, were observed in all PGL 
tissues (data not shown).
Figure 1   Respiratory chain enzyme activity in PGL tumour tissues of different genotypes.
A-E. Dot plots depicting the respiratory chain enzyme activities of respiratory chain enzyme 
complexes I to IV and Citrate Synthase (CS) across different genotypes in mU normalized to 
mg protein concentrations. Horizontal line represents the mean. Data sets having different 
alphabets above them are significantly different (P<0.05).
A
C
E
B
D
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The differences in high energy phosphate content between the tumours were 
striking. Proton NMR spectroscopy cannot discriminate between ATP, ADP and 
AMP and therefore figure 2B shows the sum of the three high energy phosphates. 
The concentration of ATP/ADP/AMP was consistently very low (p<0.0001) in all 
SDHx tumours. A very low content also occurred in the other tumour groups but 
the ATP/ADP/AMP concentration was rather variable in these groups. RET tumours 
had high ATP/ADP/AMP when compared to sporadic (p<0.01) and SDHx tumours 
(p<0.0001).
Epinephrine was proton NMR-undetectable in all SDHx and VHL tumours. The RET 
tumours showed high epinephrine concentrations when compared to sporadic 
(p<0.05), SDHx (p<0.0001) and VHL (p<0.001) tumours (Fig 2C). In SDHx tumours, 
norepinephrine was also very low when compared to sporadic (p<0.01), RET 
(p<0.0001) and NF1 tumours (p< 0.05) while 50% of the VHL tumours produced 
significant amounts of norepinephrine (Fig 2D). Total catecholamine peaks were 
below detection limit in 33 tumour samples. Seven of these samples were subjected 
to HPLC which detected the presence of catecholamines in these tissues.     
Correlation of energy metabolism with tumour tissue 
catecholamine content
Positive correlations (p<0.001) were observed between activities of respiratory 
chain complex II and concentrations of epinephrine, norepinephrine and total 
catecholamine content in tumour tissues. ATP/ADP/AMP content of PGL tumours 
also showed a positive correlation with tumour tissue epinephrine, norepinephrine 
Table 2   Comparison of respiratory chain complex activities between  
different genotypes
Genotype SDHx vs VHL vs
Sporadic MEN-2 and NF1 Sporadic MEN-2 and NF1
Complex I 0.3164 0.0278 0.0478 0.4221
Complex II < 0.0001 < 0.0001 0.1150 0.1703
Complex III 0.0050 0.0165 0.0082 0.0137
Complex IV 0.0397 0.0439 0.0600 0.0733
Note: Listed in the table are P values (adjusted) for the various comparisons. Highlighted in bold 
letters are comparisons which attained statistical significance.
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and total catecholamine levels (Table 3). Parasympathetic PGLs were excluded 
from this analysis as they do not produce catecholamines.
 Further, Passing-Bablok regression statistics for comparison between complex II 
activity, tumour ATP/ADP/AMP content and total catecholamine content demonstrated 
a linear relationship (Figure 3). 
Figure 2  Accumulation of intermediates of energy metabolism and catecholamine metabolism 
in PGL tumour tissues of different genotypes as determined by 1H-NMR spectroscopy. A. Dot 
plot depicting the tumour tissue succinate concentrations expressed as nmol per mg 
tumour tissue across different genotypes. B. Dot plot depicting the tumour tissue ATP/ADP/
AMP concentrations expressed as mmol per mg tumour tissue across different genotypes. 
C. Dot plot representing the tumour tissue epinephrine concentrations expressed as µmol 
per mg tumour tissue across different genotypes. D. Dot plot representing the tumour 
tissue norepinephrine concentrations expressed as µmol per mg tumour tissue across 
different genotypes. Horizontal line represents the mean. Data sets having different 
alphabets above them are significantly different (P<0.05). In 13 tumour samples, succinate 
and ATP/ADP/AMP and in 33 tumour samples total catecholamine peaks were below 
detection limit. They have been represented as half the lowest detectable value.
A
B
C
D
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2.4  Discussion
The present study establishes differences in mitochondrial energy pathways in 
metabolic processes in PGLs and provides novel insight into how deregulation of 
energy metabolism might impact catecholamine phenotypic features of cluster 1 
and cluster 2 tumours. Further, the study also provides ex vivo evidence for the 
accumulation of succinate in SDH-related tumours and successfully uses 1H-NMR 
spectroscopy for detection of catecholamines in PGL tumour tissues. 
 In accordance with previous reports (7-10), we observed that the activity of 
SDH or respiratory chain enzyme complex II is low in SDH-related tumours. 
Interestingly, reduction of complex II activity in SDH-related tumours was 
associated with increased activities of other respiratory chain complexes I, III and 
IV and CS. The increased CS activity also indicates an increase in the mitochondrial 
content. This observation is in agreement with report by Douwes et al., (21) in 
which elevated numbers of tightly packed mitochondria were observed in SDHD 
linked head and neck PGLs. A similar increase in activities of Complex I, III and CS 
activities in SDH-related tumours when compared to VHL-related ones was 
Figure 3  Relationship between tumour tissue catecholamine content and activity of 
respiratory chain enzyme complex II and tumour ATP/ADP/AMP content. Passing-Bablok 
regression plots for activities respiratory chain enzyme complex II (mU per mg protein) 
versus total catecholamine content (nmol per mg tissue) in PGL tumour tissues represented 
in Log10 scale. Points for samples below detection limit of 1H NMR spectroscopy are encircled 
in black.
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observed by Fliedner et al., (22). All these factors suggest a compensatory response 
to the lack of SDH activity and associated activity of complex II. However as 
currently shown, the apparently increased activity of complex I, III, IV and CS in 
the tumours does not lead to full restoration of ATP/ADP/AMP. This contrasts with 
the report of Favier et al., (7)E in which no differences for complex III activity were 
observed among NF1/RET, SDH and VHL-related PGLs and that of Rapizzi et al., (10) 
where no differences in CS activity were observed across different genotypes. 
Our findings of higher complex IV activity in SDH-related tumours than NF1 and 
RET related ones contradicts with the findings by Favier et al., (7) who observed 
a decreased Complex IV activity in SDHx and VHL-related tumours. However, 
our observations are in agreement with the increased expression of complex IV 
protein reported in four out of five SDH-related tumours by Rapizzi et al., (10). 
Nevertheless, this study also indicated a high degree of variability in complex IV 
activities in these tumours. 
 Previous studies by Lopez-Jimenez et al., (23) and Favier et al. (7) have 
demonstrated that there is a preferential activation of HIF-1α target genes such 
as glycolytic pathway enzymes in VHL tumours while activation of HIF-2α is 
observed in both VHL and SDHx tumours. It is also thought that activation of 
hypoxic response may be directly involved in decreased mitochondrial respiration. 
Interestingly, in the present study we observed an increase in complex I, III and IV 
and CS in SDHx tumours while there was a trend of overall down regulation of 
respiratory chain activities in VHL tumours. Also, we observed that in contrast to 
VHL tumours, accumulation of ATP/ADP/AMP in SDHx tumours was undetectable 
(except in one sample). This indirectly supports the observations by Favier et al., 
(7) that there is an activation of glycolysis as evidenced by increased lactate 
dehydrogenase activity in VHL tumours and not SDHx tumours. However, 
increased expressions of GLUT-1, GLUT-3 and Hexokinase II mRNAs observed in 
SDH tumours (7) can explain the high sensitivity of [18F]-FDG PET to SDH tumours 
(24-26). 
 In in vitro experiments with cells silenced for SDH, it was observed that the 
accumulation of succinate leads to stabilization of HIF-1α (11). Later, Pollard et al., 
(27) described succinate accumulation in tumour tissues with germline SDH 
mutation, however, it was described in a single patient with pathogenic SDH 
mutation. In the present study, we for the first time provide strong in vivo evidence 
to support the hypothesis that there is an accumulation of succinate in SDH-related 
PGL tumour tissues. This supports the concept that stabilization of HIF-α in SDH- 
related tumours reflects the inhibitory effects of succinate on prolyl hydroxylase. 
High succinate accumulation observed in tumours with SDHx mutations also 
makes this a reliable parameter to indicate mutations in SDH subunits or assembly 
factors. 
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 Genotype specific differences in catecholamine production by PGLs are well 
known. In the present study, our observations that tumours with mutations in 
VHL and SDHx mainly produce noradrenaline and those with mutations in RET 
and NF1 produce both adrenaline and noradrenaline support the previous findings 
by Eisenhofer et al.,(13). This difference in the catecholamine phenotype has been 
attributed to the lack of the enzyme phenylethanolamine N-methyltransferase 
(PNMT) in VHL and SDHx tumours (28). In line with the previous studies (13), we 
also observed that the tumour tissue total catecholamine content was lower in 
SDHx tumours when compared to RET and sporadic PGLs. These differences could 
be possibly attributed to the increased tyrosine hydroxylase activity in RET 
tumours (28) however, tyrosine hydroxylase activity or expression has not been 
investigated in SDHx tumours in comparison with other genotypes albeit a lack of 
the expression of this enzyme has been observed in biochemically silent SDHB 
tumours (29).  
 In the present study we established that tumour tissue concentrations of 
ATP/ADP/AMP, as determined by low peak heights at relevant resonance positions 
in 1H-NMR spectra, are lower in SDH-related tumours than in other tumours. 
Further, our findings of positive relationships between respiratory enzyme 
complex II function, tumour ATP/ADP/AMP content and tumour catecholamine 
contents suggest the possibility that differences in energy metabolism might also 
contribute to the lower tumour tissue catecholamine contents in cluster 1 than in 
cluster 2 tumours. To this end, it is well known that the sequestration of 
catecholamines into secretory vesicles and re-uptake of catecholamines into 
chromaffin cells are active energy dependent processes. Sequestration of 
catecholamines is facilitated by vesicular monoamine transporters (VMATs). The 
H+ gradient necessary to maintain the activity of VMATs is generated by ATP 
dependent vesicular membrane proton pump (30). Chromaffin granules also 
contain strikingly high concentrations of ATP due to the activity of vesicular 
nucleotide transporter (31). This contributes to the stability and ability of 
chromaffin granules to maintain stores of catecholamines (32, 33). Further, 
norepinephrine transporter (NET) responsible for the sodium-chloride (Na+/
Cl–)-dependent reuptake of extracellular norepinephrine and dopamine is also 
indirectly dependent on cellular store of ATP. NET functions by coupling the 
transport of norepinephrine and dopamine with the influx of sodium and chloride 
(Na+/Cl–). The ion gradients of Na+ and Cl- generated by the Na+/K+-ATPase make 
this reuptake energetically favorable (34, 35). Clearly therefore, energy metabolism 
has an important role in maintaining the stability of chromaffin granules and 
thus catecholamine storage. It thereby seems possible that genotype specific 
differences in the energy metabolism, along with associated differences in 
expression of various genes encoding components of secretory pathway and 
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exocytotic machinery (36), could in conjunction contribute to genotype specific 
differences in tumour catecholamine phenotypic features.
 In the present study we included 35 sporadic tumours 60% of which were not 
tested for SDHA and SDHAF-2. Two of the 3 sporadic tissues which had low 
respiratory chain complex II activities comparable to SDHx tumours also belong 
to the groups which were not tested for SDHA and SDHAF-2. Thus, mutations in 
SDHA and SDHAF-2 cannot be ruled out in these tumours. Also, the low activity 
may indicate that these tumours may have an as yet unidentified intronic or 
promotor mutations in SDH subunit genes or unidentified mutations in assembly 
factors genes.  
 We used 1H NMR spectroscopy to determine the tumour tissue metabolite 
concentrations as it provides a holistic view on the tumour metabolome. This 
technique can very well identify various metabolites and quantify differences in 
the metabolite concentrations among different samples, but it is limited by its 
sensitivity. It can quantify metabolites only in micromolar range because of 
which, many intermediates of energy and catecholamine metabolism could not 
be determined in the present study.  This is clearly visible in the Passing-Bablok 
regression analysis of total catecholamines vs Complex II activity and ATP/ADP/
AMP levels where reduced sensitivity of NMR spectroscopy separates out a group 
of samples which if analyzed with a more sensitive method could have reflected 
the linear relationship better. Nevertheless, the study was successful in 
identifying the relationship between catecholamine content of PGLs and energy 
metabolism. 
 Catecholamine contents are particularly low in tumours due to SDHB 
mutations and it has been suggested that this along with diversion of energy 
from maintaining catecholamine phenotypic features to growth might contribute 
to the larger sizes and more aggressive features of these tumours (18). The present 
study, establishing relationships between tumour energetics and catecholamine 
phenotypic features, provides new insight into how such diversions of energy 
might occur with implications for novel therapeutic strategies targeting energy 
pathways.
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Supplementary Figure 1  Examples of 1H NMR spectra for different genotypes A. Example 
of NMR spectrum of a sporadic tumour depicting the peak positions of lactic acid, acetic 
acid and catecholamines. B. Example of NMR spectrum of a SDHB tumour depicting peak 
position of succinic acid. C. Example of NMR spectrum of a RET tumour depicting ATP/ADP/
AMP and adrenaline specific peaks.
A
B
C
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Supplementary Figure 2  Comparison of epinephrine and norepinephrine content in tumour 
tissues as determined by HPLC and 1H-NMR spectroscopy. Passing - Bablok regression plot to 
compare measurement of epinephrine and norepinephrine content in PGL tumour tissues 
by HPLC and 1H-NMR spectroscopy expressed as µg per mg tissue in Log10 scale.
Supplementary Figure 3  Activities of respiratory chain complex II and tumour tissue 
succinate content in SDH related tumours. Black bars represent complex II activity expressed 
in mU/mg protein and grey bars represent tumour tissue succinate content in mmol/mg 
tissue for each individual tumour. Represented on X axis is the hereditary mutation in the 
patient from whom the tumour was resected.
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Abstract
Context and Objective: Pheochromocytomas and paragangliomas (PGLs) are 
neuroendocrine tumours of sympathetic or parasympathetic paraganglia. Nearly 
40% of PGLs are caused by germline mutations. The present study investigated 
the impact of genetic alterations on metabolic networks in PGLs. 
Design: Homogenates of 32 sporadic PGLs and 48 PGLs from patients with 
mutations in SDHB, SDHD, SDHAF-2, VHL, RET and NF-1 were subjected to 1H-NMR 
spectroscopy at 500 MHz for untargeted and HPLC tandem mass spectrometry for 
targeted metabolite profiling. 
Results: 1H-NMR spectroscopy identified 28 metabolites in PGLs of which 12 
showed genotype-specific differences. Part of these results published earlier 
reported low complex II activity (p<0.0001) and low ATP/ADP/AMP content 
(p<0.001) in SDH-related PGLs compared to sporadics and PGLs of other genotypes. 
Extending these results, low levels of N-acetylaspartic acid (NAA, p<0.05) in SDH 
tumours and creatine (p<0.05) in VHL tumours were observed compared to 
sporadics and other genotypes. Positive correlation was observed between NAA 
and ATP/ADP/AMP content (p<0.001) and NAA and complex II activity (p<0.0001) 
of PGLs. Targeted purine analysis in PPGLs showed low adenine in cluster 1 
compared to cluster 2 tumours (SDH p<0.0001; VHL p<0.05) while lower levels 
(p<0.05) of guanosine and hypoxanthine were observed in RET tumours compared 
to SDH tumours. Principal component analysis (PCA) of metabolites, could 
distinguish PGLs of different genotypes. 
Conclusions: The present study gives a comprehensive picture of alterations in 
energy metabolism in SDH- and VHL-related PGLs and establishes the interrela-
tionship of energy metabolism and amino acid and purine metabolism in PGLs.
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3.1  Introduction
Pheochromocytomas and paragangliomas (PGLs), are neuroendocrine tumours of 
the adrenal medulla and sympathetic or parasympathetic paraganglia (1). Nearly 
40% of them are caused by germline mutations in tumour susceptibility genes 
which include VHL (von Hippel-Lindau), RET (rearranged during transfection), 
NF-1 (neurofibromatosis type 1), SDHA/B/C/D/AF2 (succinate dehydrogenase subunits 
A, B, C and D and assembly factor 2), TMEM127 (transmembrane protein 127), 
MAX (myc-associated factor X) (2) and more recently discovered HIF2α (Hypoxia 
inducible factor 2 α) (3) and FH (fumarate hydratase) (4). Gene expression profiling 
has revealed the presence of two clusters of PGLs: cluster 1 (VHL, SDH) and cluster 
2 (RET, NF-1, TMEM127 and MAX) displaying signature of transcripts associated 
with angiogenesis and hypoxia and RNA synthesis and kinase signaling, 
respectively.
 Previous studies by us and others demonstrate a genotype-specific alteration 
in respiratory chain enzyme activities (5-7). In comparison with other genotypes, 
VHL tumours show an overall decrease in respiratory chain enzyme function, 
while SDH tumours demonstrate a decreased complex II and an attempted 
compensatory increase in the complex I, III and IV activities, indicative of impaired 
mitochondrial function (6). Mitochondria are the metabolic hubs of the tumour 
which in addition to providing energy, generate reducing equivalents (NADH 
and NADPH) and intermediates for anabolic reactions. Thus, genotype-specific 
differences in the mitochondrial function could have a strong impact on inter- 
mediary metabolism of PGLs beyond aerobic glycolysis.
 In this scenario, use of metabolomic techniques help to discover and 
systematically analyze the metabolic fingerprint of the tumours thus giving 
insights into alterations in the metabolic pathways that are involved in 
tumourigenesis (8). Proton (1H) nuclear magnetic resonance (NMR) spectroscopy 
is a cornerstone technology for untargeted metabolomics. It provides a holistic 
view of metabolism and has other advantages like relatively simple sample 
preparation and rapid data acquisition. Moreover, it allows quantitation of large 
number of metabolites using a single internal standard (9,10). 
 In the present study, we used a combination of 1H NMR spectroscopy and 
liquid chromatography (LC) tandem mass spectrometry (MS) to investigate geno-
type-specific differences in the metabolic profile of 80 PGLs. 1H NMR spectroscopy 
was used for untargeted metabolite profiling and LC tandem MS was used to 
further investigate and/or validate the findings obtained from 1H NMR 
spectroscopy.
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3.2  Materials and Methods
Patients 
In the present study, tumours of patients with histologically proven PGLs 
evaluated at the Radboud University Medical Centre (RUMC), Nijmegen, the 
Netherlands (n=52) and Eunice Kennedy Shriver National Institute of Child Health 
and Human Development (NICHD) (n=24), National Institute of Health (NIH), 
Bethesda, MD, USA who underwent surgical resection between 1988 and 2012 and 
between 2003 and 2010 respectively, were included. Frozen primary tumours 
were used for the study. No metastatic tumours were used. The presence of 
germline mutations and large deletions in SDHB/C/D, RET, VHL and -since 2011- in 
SDHA, SDHAF2, TMEM127 and MAX, was investigated using standard procedures. 
Data were collected under conditions of regular clinical care, with ethical 
committee approval for the use of those data for scientific purposes at RUMC. The 
study was approved by the Institutional Review Board of NICHD, and all patients 
gave written informed consent before testing. The details of the patients’ clinical 
characteristics, tumour location and genotype are listed in Table 1. Tumours from 
patients in whom germline mutation could not be found in any of the PGL-genes 
were considered “sporadic”. The extraadrenal tumours were mainly abdominal 
(retroperitoneal) or thoracic in location.
Tumour tissue processing and sample preparation
Tumours were procured as early as possible, dimensions were recorded and a 
small piece of the tumour was weighed, snap frozen, stored in liquid nitrogen and 
used for experimental purposes. For histological confirmation, additional slices 
were stained with hematoxylin and eosin and re-evaluated by an independent 
pathologist (BK).
 The tumour tissues were homogenized on ice in 10µl of ice cold distilled water 
per mg tissue using a hand-held Teflon/glass homogenizer. The samples were 
then centrifuged at 16,000xg for 10min at 4oC and the supernatants were subjected 
to ultrafiltration with Vivaspin Turbo15, 10kDa filters (Sartorius, Germany) for 
deproteinization.
 
1H NMR Spectroscopy 
One-dimensional 1H NMR spectroscopy was performed to investigate the 
metabolic profile of PGLs. For this purpose, the total ultrafiltrate was made up to 
700µl with water, pH was adjusted to 2.5 and 20µl of 20.2mM sodium 3-trimethyl-
silyl-2,2,3,3-tetradeuteropropionate (TSP, Aldrich, Zevenaar, The Netherlands) in 
D2O (Catalogue No. 435767, Aldrich, Zevenaar, The Netherlands) was added to the 
samples. The samples were then placed in 5mm NMR tubes and 1H NMR spectra 
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were obtained using a Bruker 500MHz spectrometer (pulse angle 90o, delay time 
4s, number of scans 256). Water resonance was suppressed by gated irradiation 
centred on the water frequency. For resonance assignment, 2D COSY NMR spectra 
were acquired for some of the samples. The spectral width in the F1 and F2 domains 
were 5500Hz. A total of 2K data points were collected in t2, 256 t1 increments with 
32 transient per increment were used. The relaxation delay was set to 2s. Before 
the Fourier transformation, a sine-bell function was applied in both time domains. 
During the relaxation delay, the water resonance was presaturated.
 
Analysis of NMR spectra
The free induction decays (FIDs) measured for these samples were processed using 
Topspin software (Bruker, Germany). Fourier transformation was applied on the 
FID of the samples and the resulting spectra were phase and baseline corrected. 
The chemical shifts in the spectra were referenced to the internal standard, TSP. 
Assignment of peak positions for compound identification was performed by 
comparing the peak positions in the spectra of PGLs with the reference spectral 
database of model compounds at pH 2.5 using Amix version 3.9.14 (BRUKER 
BIOSPIN GmbH, Rheinstetten, Germany) (11,12). Quantification of identified 
compounds was performed by manual integration of chosen peak/s for a specific 
metabolite. Further confirmation of metabolite identification based on peak 
positions was obtained from 2D NMR.
Table 1   Patient Characteristics
Genotype N  
(patients)
Age y
(mean±SD)
Gender 
(M/F)
N 
(tumours)
Tumour  
location  
(A/E/HN)
Tumour  
volume  
(cm3)
Sporadic 32 45.8 ± 13.9 15/17 32 29/3/0 227.7 ± 480.1
SDHB 9 31.6 ± 11.2 8/1 11 1/10/0 295.7 ± 335.5
SDHD 8 44 ± 10.5 6/2 8 1/1/6 27.9 ± 47.2
SDHAF2 1 24 1/0 1 0/0/1 18.9
VHL 7 31.4 ± 10.5 6/1 7 6/1/0 70.9 ± 97.8
RET 12 37.7 ± 13.3 6/6 14 14/0/0 97.6 ± 179.4
NF1 7 43.1 ± 18.9 4/3 7 7/0/0 115.7 ± 85.2
N: Number, y: years, M: Male, F: Female, A: Adrenal, E: Extra-adrenal, HN: head and neck
46
High pressure liquid chromatography (HPLC) tandem mass 
spectroscopy (MS):
Deproteinized tumour tissue lysate was used for targeted measurement of 
purines using LC tandem mass spectrometry. Only PGLs with known hereditary 
mutations (n=47, one VHL tumour excluded for limited sample quantity) were 
included in this experiment. The samples were prepared by adding 100µl of stable 
isotope internal standard solution containing dihydrouracil, uracil, uric acid, 
orotic acid, dihydrothymine, thymine, guanosine and thymidine and 10µl of 2% 
formic acid for acidification to 100µl of deproteinized tumour tissue lysate. 5µl of 
the sample thus prepared was injected into the HPLC tandem MS system. The 
HPLC tandem MS process is described in detail in supplementary information.
Multivariate Statistical Analysis
A total of 45 1H NMR spectra corresponding to 13 RET, 7 NF-1, 18 SDH and 7 VHL 
tumours were considered for PCA. Spectra from 1 RET and 2 SDH tumours were 
omitted in the analysis as the quality of the spectra was not suitable for PCA. PCA 
was also performed on purine concentrations normalized around mean from 20 
SDH, 6 VHL, 14 RET and 7 NF-1. For details see supplementary methods.
Confirmation of metabolites identified by 1H-NMR spectroscopy
Independent targeted and quantitative HPLC and LC tandem MS methods were 
used for confirmation of detection and quantitation of succinate and N-acetylas-
partic acid (NAA) (see supplementary information).
Statistical methods
Statistical analyses were performed using SPSS (SPSS Inc., v.18, Chicago, IL) and 
GraphPad Prism 6 software (GraphPad, La Jolla, CA). The data was analyzed using 
independent samples Kruskal-Wallis test and Dunn’s post-test was used to 
compare the different genotypes. Statistical significance was accepted at P <0.05. 
3.3  Results
Overview of 1H-NMR spectra of PGLs
NMR spectroscopy was performed in all 80 PGLs. The spectra showed resonances 
of 28 different metabolites (Fig 1 and Table 2). Among these are amino acids, 
sugars, intermediates of Krebs cycle and glycolysis, catecholamines, organic acids, 
high energy phosphates, creatine/creatinine, NAA and N-acetylaspartylglutamic 
acid.
47
Genotype Specific Differences in PGL Metabolome
3
Genotype-specific differences in the metabolites as identified  
by 1H-NMR spectroscopy
NAA content of the tumour tissue was estimated by integrating the area under the 
peak at 2.03ppm. This peak was chosen as the multiplets at 2.94 and 4.72 overlapped 
with those of N-acetylaspartylglutamic acid. NAA was below detection limit in all 
the SDH and VHL tumours tested except one (Fig 2E, supplementary fig 4). The levels 
were higher in RET (p<0.01), NF-1 (p<0.05) and sporadic tumours (p<0.05) when 
compared to SDH tumours (Fig 2E). NAA peaks were undetectable in 16 sporadics, 
3 RET and 3 NF-1 tumours. HPLC tandem MS was used to validate the NAA content 
of the tumours and a significant correlation and linear relationship was observed 
between the two methods (supplementary fig 1).
 Creatine concentrations in tumours were estimated by integrating the area under 
peak at 3.05ppm as the singlet at 4.11ppm had a lower signal to noise ratio and also 
Figure 1  One dimensional 500 MHz 1H NMR spectra of PGLs tumour tissues at pH 2.50 A. 
Sporadic tumour showing normal tumour metabolites such as lactic acid, acetic acid and 
catecholamines. B. SDHB tumour showing a high concentration of succinic acid (9.89 nmol/
mg tissue). C. RET tumour showing high resonance of epinephrine and the overlap of the 
three doublets deriving from ATP/ADP/AMP.
A
B
C
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Table 2     NMR assignmenta (pH 2.50) and occurrence for metabolites observed 
in PGLs of different genotypes
Metabolites δ 1H Genotype
SDH VHL RET NF-1 Sporadic
Acetic acid 2.08 s ++ ++ ++ ++ ++
N- Acetylaspartic acid 2.03 s - + + + +
N- Acetylglutamylasparagine 2.05 s - - + (n=6) - + (n=4)
4- Aminobutyric acid 2.50 t + + + + +
ATP/ADP/AMP 6.20b d - + + + +
Citric acid 2.92 AB - - - - + (n=4)
Creatine 3.05 s; 4.11 s ++ + ++ ++ ++
Creatinine 3.13 s; 4.29 s ++ + ++ ++ ++
Epinephrine 2.73 t - - ++ ++ ++/-
Ethanol 1.17 t; 3.64 q ++ ++ ++ ++ ++
Formic acid 8.24 s + + + + +
Glutamate/Glutamine 2.17 m + + + + +
Histidine 8.67 d - + (n=1) + - -
3- Hydroxybutyric acid 1.23 d + + + + +
Inosine 6.09 d; 8.22 s + ++ ++ ++ ++
Inositol-myo 3.27 t; 4.05 t + + + + +
Inositol-scyllo 3.34 s + + + + +
Isoleucine 0.94 t; 1.02 d + + - + +
Lactic acid 1.41d; 4.36 q +++ +++ +++ +++ +++
Lysine 1.72 m + + + + +
Methanol 3.35 s ++ ++ ++ ++ ++
Methionine 2.12 s + + + + +
Norepinephrine 6.90 m + + ++ ++ ++
Pyruvate 2. 37 s + + + + +
Succinic acid 2.67 s +++ + + + +
Sucrose 5.40 d - - - - ++ (n=2)
Threonine 1.33 d + + + + +
Unknown 2.14 s + - - - -
Valine 1.00 d; 1.04 d + + + + +
+: Present in spectrum, +: low; ++: medium +++: high; based on peak heights
– :  Absent in spectrum 
a:  Chemical shifts (δ) in ppm relative to TSP; multiplicity are s, singlet; d, doublet; t, triplet; q, quartet; 
m, multiplet; AB, AB system (second order coupling). 
b: overlap of three doublets
n: Number of patients in whom the metabolites was found 
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was in a region with peaks arising from several other metabolites. Creatine levels 
were high in NF-1 tumours when compared to SDHD/AF2 head and neck PGLs 
(p<0.01), VHL (p=0.0001) and RET (p<0.05) tumours (supplementary fig 4). VHL 
tumours had low creatine levels when compared to sporadic tumours (p<0.05) 
(Fig 2F). Creatine peaks were undetectable in 1 sporadic and 2 RET related PGLs.
 Isoleucine levels in the tumour tissue were determined by integrating area 
under peaks for the doublet at 1.02ppm as this doublet resonance had the best 
signal to noise ratio. Isoleucine peaks were consistently undetectable in RET 
tumours while in the tumours of other genotypes the levels were measurable 
(Fig 2D) though its levels were found to be undetectable in 9 sporadic, 5 SDH, 3 VHL 
and 3 NF-1 tumours.
 The as yet unassigned singlet resonance at 2.14ppm occurs in all SDH tumours. 
The concentration of the compound causing this resonance must be in the low 
micromolar range. As the singlet partially co-resonates with the glutamine multiplet 
resonance at 2.17ppm it is hard to decide whether the 2.14ppm singlet also is 
present in lower concentration in the other tumour types. Clearly, the concentration 
of the metabolite causing the 2.14ppm singlet in the SDH tumours is significantly 
higher than in the other tumour types.
Correlation of NAA content with energy metabolism in PGLs
Positive correlations were observed between NAA and ATP/ADP/AMP content 
(R=0.422, p<0.001) and NAA content and activity of respiratory chain complex II 
(R=0.465, p<0.0001) in PGL tumours.
Multivariate statistical analysis of NMR results
Using PCA without scaling, tumours with mutations in SDHB, VHL and RET could 
be well separated based on the variances in the peak positions pertaining to 
epinephrine, succinate, ATP/ADP/AMP, an unknown peak at 2.14ppm and lactic 
acid (Figure 2D and E). High levels of epinephrine in RET tumours, increased 
succinate accumulation and low levels of ATP/ADP/AMP in SDH tumours and 
higher levels of lactic acid in VHL tumours when compared to RET tumours are 
identified in the PCA as most discriminating features. NF-1 tumours from two 
patients were classified with VHL tumours as they contained higher lactic acid 
levels and epinephrine levels below the detection limit of NMR spectroscopy. The 
NF-1 tumours did not form a separate group as there was no single distinguishing 
metabolite detectable by 1H-NMR spectroscopy for this group. To highlight the 
subtle differences and to minimize the effect of high intensity peaks, PCA was 
also performed after autoscaling which revealed threonine (1.33ppm) and alanine 
(1.51ppm) peaks contributing to the separation of SDH tumours from the RET 
tumours.
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Genotype-specific differences in Purine metabolism in PGLs
Observations of consistent lack of ATP/ADP/AMP peaks in SDH tumours when 
compared to the other genotypes could probably be related to altered purine 
biosynthetic pathways in SDH related PGLs. Thus, purine concentrations were 
estimated using HPLC-tandem MS in PGL lysates prepared for 1H NMR spectroscopy. 
 Adenine levels were lower in SDH tumours when compared to RET and NF-1 
tumours (p<0.0001 and p<0.05, respectively). Adenosine levels were lower in SDH 
(p<0.01) and VHL (p<0.05) tumours when compared to RET tumours in contrast to 
guanosine which was higher in SDH tumours when compared to RET tumours 
(p<0.05). Inosine levels were lower in cluster 1 tumours compared to those 
belonging to cluster 2 (p<0.01) differing from hypoxanthine which was higher in 
SDH tumours when compared to RET related ones (p<0.05, Table 3).
Multivariate statistical analysis of purines
Using PCA, the samples with mutations in SDH, RET and NF-1 could be separated 
based on the differences in the concentrations of adenine, hypoxanthine and 
inosine (supplementary figure 2). High levels of adenine in RET and hypoxanthine 
in SDH tumours emerge as the most discriminating features for these tumours in 
the PCA analysis.
Table 3   Overview of purines (mg/mg tissue) detected in PGLs
Metabolites Genotype
Cluster 1 Cluster 2
SDH (n=20) VHL (n=6) RET (n=14) NF-1 (n=7)
Adenine 0.68 ± 0.80a 3.3 ± 4.11 a,c 16.18 ± 5.41b 8.33 ± 6.95b,c
Adenosine 1.33 ± 2.84 a 6.53 ± 12.67 a,b 3.59 ± 2.93b 5.65 ± 5.67 b
Guanine 7.3 ± 6.73 2.9 ± 3.29 3.08 ± 1.29 2.01 ± 1.10
Guanosine 4.44 ± 5.26 b 4.51 ± 5.54 a,b 0.86 ± 0.9a 1.79 ± 1.60 a,b
Inosine 23.35 ± 20.15 a 47.42 ± 36.10 a,b 40.26 ± 19.44a,b 78.32 ± 67.70 b
Hypoxanthine 103.73 ± 48.28 b 116.16 ± 50.70 a,b 64.16 ± 19.46 a 96.49 ±  47.22 a,b
Xanthine 14.52 ± 15.58 20.22 ± 15.47 12.71 ± 6.60 15.96 ± 6.87
Uric Acid 64.25 ± 147.32 11.58 ± 4.21 31.76 ± 63.92 23.10 ± 28.38
a and b: a Values are significantly lower than b values (where b is P< .05) when indicated after unique 
values. c No significant differences were observed between the two groups.
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3.4  Discussion
The present study extends the results of genotype-specific differences in metabolic 
profiles of PGLs from our previous publication using the same set of tumours (6). 
In the previous study using the same set of PGLs we reported decrease in complex 
II activity (p<0.0001), increase in succinate content (p<0.001) and decrease in ATP/
ADP/AMP content (p<0.001) in SDH tumours when compared to sporadic PGLs and 
PGLs of other genotypes. Further, we discussed the interrelationship of energy 
and catecholamine metabolism (6). In the present study, we have used multiple 
complementary analytical methods, to further investigate genotype-specific 
differences in tumour metabolite profile. Here we describe genotype-specific 
differences in the contents of additional metabolites and demonstrate that these 
differences in metabolite profiles can be used to differentiate the genotypes using 
unsupervised statistical methods. The study thus gives a comprehensive picture 
of alterations in energy metabolism in SDH and VHL tumours. Further, interrela-
tionships of genotype-specific alterations in energy, amino acid and purine 
metabolism are established.
 Metabolite profiling of tumours has been approached using two basic 
technological platforms, NMR or MS. In the present study, we have used multiple 
complementary analytical techniques which use both of these platforms. We 
used NMR as an untargeted metabolite profiling technique allowing detection of 
the vast majority of proton containing compounds in the low micromolar or 
higher concentration range. For targeted metabolite profiling, we used HPLC 
tandem MS to test the presence of genotype-specific differences in the 
concentration of various purines in the tumours.
 NMR based metabolite profiling has the inherent disadvantage of limited low 
micromolar sensitivity which limits the number of metabolites that could be 
identified. Thus, we were unable to generate a metabolomic profile of sufficient 
complexity for unbiased application of pathway analysis tools to identify geno-
type-specific dysfunctional metabolic pathways. 
 We used PCA as an unsupervised method for interpretation of NMR spectra 
and to classify the samples in genotype-specific groups on the basis of their 
metabolite profile. The peak positions contributing to maximum variability in the 
first three principal components included epinephrine, succinate, lactic acid and 
high energy phosphates of adenosine. This is explained by their respective roles in 
catecholamine and energy metabolism. Interestingly, high lactate levels observed 
in VHL tumours support the observations of high LDH activity in these tumours 
by Favier et al (5). However, the results need to be interpreted with caution as 
lactate levels in resected samples do not necessarily reflect the actual tumour 
metabolism. Despite alanine and threonine emerging as important variables 
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after autoscaling, significant differences were not observed for these amino acids 
among the tumours of different genotypes when the concentrations of these 
amino acids were calculated based on the area under peak of the NMR spectra.
 Reduced tumour ATP/ADP/AMP content as measured by 1H-NMR spectroscopy, 
suggested that there could be a reduced total adenylate, adenosine and adenine 
content in the SDH tumours. This hypothesis was verified by assessing content of 
purines in PGLs using HPLC tandem MS. Based on the results of this study, we 
hypothesize that in the de novo synthesis of the purine nucleotides, possibly the 
activity of inosine monophosphate (IMP) dehydrogenase is higher in SDH tumours 
while in the RET related ones, adenylosuccinate synthase and/or lyase activities 
are higher. Thus, the IMP that is formed by the de novo pathway is committed to 
either of the purine biosynthetic branches in a genotype-specific way (Figure 3). 
In a similar situation, Pillwein et al., (13) compared the normal brain tissue and 
glioblastomas for pool of purines and purine nucleotides and nucleosides and the 
activities of IMP dehydrogenase, hypoxanthine guanine phosphoribosyl 
transferase (HGPRT) and other enzymes. It was observed that total adenylates 
and guanylates were lower by 60% and 71% respectively and that incubation of 
such tumour sections with Tiazofurin, an IMP dehydrogenase inhibitor lead to a 
reduction in total guanylate pool. Additionally, the enzyme HGPRT in the salvage 
pathway might have genotype-specific differences in substrate availability 
which leads to the differences in their purine nucleotide profile. A recent report by 
Gottle et al. (14) showed that increased purine nucleotide pools and energy reserve 
are observed post differentiation in rat pheochromocytoma cells (PC-12 subclones) 
which indirectly suggests that the lower purine pools are reflective of dedifferen-
tiation. However, in contrast to the observations of Gottle et al., (14) that undiffer-
entiated cells have lower dopamine, SDH tumours have high dopamine levels. 
Thus, it is not clear whether purine pool has an effect on dopamine levels in 
hereditary PGLs. Further, using PCA of purine levels in PGLs, SDH, RET and NF-1 
tumours could be distinguished well. However, genotype-specific differences 
were not observed in levels of more downstream metabolites of purine 
biosynthetic pathway like xanthine and uric acid indicating lack of genotype-spe-
cific differences in further purine catabolism.
 In this study, for the first time we report the presence of NAA in the peripheral 
nervous system. NAA is synthesized through acetylation of aspartate by 
L-Asparatate N-acetyl transferase, a membrane bound enzyme, in the neuronal 
tissue (16). NAA is synthesized and exported from mitochondria and its synthesis 
is dependent on mitochondrial energy state. Mitochondrial NAA production is 
dependent on functioning of respiratory chain enzyme complexes and oxidative 
phosphorylation. Inhibition of these enzymes leads to significant decrease in 
mitochondrial NAA and ATP production in isolated rat brain mitochondria (17). 
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This relates well with our observation of strong positive correlation between NAA 
content and respiratory chain complex II activity and NAA and ATP/ADP/AMP 
contents in PGLs. Further, we observed low NAA/total creatine ratio in tumours 
with compromised mitochondrial function (supplementary figure 3). Similar 
observations have also been made in patients with mitochondrial encephalomy-
opathies (18). Thus, the NAA levels in SDH and VHL tumours are directly linked to 
the energetic states of the tumour cell mitochondria. 
Figure 3  Purine metabolism pathway. Enzymes involved are: adenylosuccinate synthase (1), 
adenylosuccinate lyase (2), IMP dehydrogenase (3), adenosine deaminase (4), purine-nucleoside 
phosphorylase (5), xanthine dehydrogenase (6), hypoxanthine-guanine phosphoribosyl  transferase 
(7), adenine phosphoribosyl transferase (8). PRPP, 5-phospho-a-D-ribosyl-1-pyrophosphate; 
SAICAR, succinylaminoimidazole carboxamide ribotide; AICAR, aminoimidazole carboxamide 
ribotide; FAICAR, formylaminoimidazole carboxamide ribotide; S-AMP, adenylosuccinate; 
S-adenosine, succinyladenosine. Figure adopted from Wevers et al., 1999 (15).
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 In our studies, we show the presence of high levels of lactate in some of the 
VHL tumours which also show low NAA and total creatine levels. In similar 
observations, 1H NMR spectroscopic imaging of rat gliomas in vivo also 
demonstrated reduced NAA levels in tumours associated with high glycolytic 
activity (19). Also, it has been observed that in tissues with ischaemic stroke there 
is increased anaerobic glycolysis as evidenced by increased levels of lactate in the 
lesion and the border zone brain tissue. Increased lactate levels in these tissues 
were associated with decreased NAA and total creatine levels. This was also 
associated with decreased glutamate and glutamine levels in the affected brain 
tissue (20). However, though we observed highly reduced NAA and reduced total 
creatine levels in tumours associated with increased aerobic glycolysis, the 
glutamate + glutamine levels were not different from other tumours. In SDH 
tumours, lower glutamate levels were observed compared to sporadic and VHL 
tumours by Imperiale et al. (21) using 1H high resolution magic angle spinning 
NMR spectroscopy in small tumour pieces. However, in the spectra of the present 
study obtained using homogenized tissue, glutamine and glutamate peaks were 
not clearly separated to verify the above mentioned report. Thus, estimation of 
levels of glutamate and glutamine with other methods might help in giving more 
clarity. 
 Creatine serves as an energy reservoir and mode of energy transport within 
a cell by accepting a phosphate group in mitochondria through the activity of 
creatine kinase. Phosphorylated creatine can be shuttled to different cellular 
regions in need of high energy phosphate group to regenerate ATP. In cells with 
low energetic status, phosphocreatine levels are low. The reduction in total 
creatine levels as observed by us in VHL tumours is suggestive of larger alterations 
in cellular energy metabolism. In particular, it reflects a lack of sufficient ATP 
levels to maintain stores of phospho-creatine which might lead to efflux of 
cellular creatine stores. This might be reflected as low creatine levels in SDH and 
VHL tumours when compared to NF-1 tumours. Further, grouping of SDH tumours 
based on the tumour localization did not reveal location specific alterations in the 
metabolite levels. Thus, the tumour metabolism, as observed in the present study, 
tended to be influenced more in a genotype-specific way.
 In conclusion, alterations in energy metabolism caused by hereditary mutations 
are associated with alterations in catecholamine, amino acid and purine metabolism 
which could in addition to energy metabolism be targeted in these tumours for 
diagnostics and therapeutics.
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3.6  Supplementary Methods
HPLC tandem MS
The HPLC tandem MS system consisted of a Quattro premier XE tandem MS 
(Micromass MS technologies, Waters, The Netherlands) in combination with an 
Acquity Ultraperformance LC (Waters, the Netherlands). Using the autosampler 
5µl aliquots of prepared samples were injected on to an Atlantis T3 column (10cm, 
particle size 3µm). The mobile phase consisted of A: 0.3% formic acid in water and 
B: 100% methanol. Samples were eluted by running a step-wise gradient (99.5% 
buffer A from the start, 87.5% at 4.75min, 75% at 5.25min and 50% at 5.75min). Total 
run time amounted to 12.3min.
 The HPLC flow was directed to the tandem mass spectrometer fitted with an 
electrospray ionization probe operated in positive mode at unit resolution. The 
capillary voltage was set at 3kV.  Settings for mass transitions and cone- and 
collision cell voltages were optimized for each component. Quantification was 
performed using an area based linear regression curve derived from the stable 
isotope diluted calibration standards.
Multivariate Statistical Analysis
To build the data matrix, variable sized bucketing was performed between 10.00 
– 0.50 ppm. The spectral regions between 5.2-4.5ppm, 3.8-3.3ppm and 1.19-1.15ppm 
were excluded from the bucket analysis to avoid the variation effects of water 
presaturation, methanol and ethanol residues, respectively. Signals showing 
larger chemical shift variations were compiled into broader buckets; for example 
alanine (bucket size 0.05; region 1.54 – 1.49 ppm). Bucket integrals were divided by 
the total spectral intensity. Bucketing was carried out in Amix version 3.9.14 
(BRUKER BIOSPIN, Germany). To preserve natural differences in intensities and to 
highlight dominant effects, no scaling was performed before PCA. Principal 
Component Analysis (PCA) was performed using Unscrambler (CAMO Software 
AS, Oslo, Norway). PCA was performed without scaling to preserve natural 
differences in intensities and to highlight dominant effects. Further, to decrease 
the importance of the high intensities and find more subtle differences PCA was 
also performed after autoscaling (Supplementary figure 5). 
Confirmation of metabolites identified by 1H-NMR spectroscopy
Confirmation of the identified metabolite peak and validation of the concentrations 
as determined by 1H NMR spectroscopy were carried out for 1H NMR spectroscopic 
measurements of succinic acid and N-acetylaspartic acid (NAA) as their 
concentrations were measured by estimating the area under the curve for single 
peaks or singlets.
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Correlation between metabolite concentrations as measured by 1H NMR 
spectroscopy and validated by other techniques was examined using Spearman’s 
correlation test and linear relationship was tested using Passing-Bablok regression 
analysis.
Determination of succinate by UPLC-MS/MS:
Metabolite extraction: Fresh frozen tumour tissue (5-10 mg) was immersed in 
500µl LC/MS grade methanol containing the internal standard 13C4-succinate 
(Catalogue No. 719269, Sigma-Aldrich, Germany). Homogenisation was achieved 
by vortexing with a metal bead for 2 minutes. Homogenates were transferred to a 
new tube and centrifuged at 2000xg for 5 minutes at 4°C to separate insoluble 
debris. Supernatants were taken to dryness with a speed vac concentrator (Thermo 
Scientific) and stored at -80°C. Pellets were resuspended in mobile phase and 
filtered using a centrifugal tube with 0.2 µm pore size.
 UPLC-MS/MS: UPLC-MS/MS analysis was carried out using an API QTRAP 
5500 (AB Sciex) coupled to an Acquity UPLC system (Waters). Chromatographic 
separation was achieved on a Waters Acquity UPLC® HSS T3 column (1.8 µm, 2.1 x 
100 mm) with a flow rate of 0.459 ml/min, a mobile phase of 0.2% formic acid in 
water (A) and 0.2% formic acid in acetonitrile (B), and a gradient of 0.37min 95% A, 
4.87min 70% A, 5.37min 100% B, 5.87min 100% B, 6.37min 95% A, 7.5min 95% A. The 
column was maintained at a temperature of 25°C and the sample manager of 5°C. 
The mass spectrometer was operated at 550°C in negative ion electrospray mode. 
Multiple reaction monitoring was used for detection. Quantification and 
qualification of succinate was performed with the transitions 117/73 and 117/99, 
respectively. For the internal standard a transition of 121/76 was used.
 The Succinate content of the tumour tissue was validated using ultra 
performance liquid chromatography tandem MS (UPLC-MS/MS) for a subset of 
samples. A good and linear correlation was observed between two methods 
(supplementary fig 2). 
Determination of N-acetyl aspartic acid by HPLC tandem MS:
Deproteinized tumour tissue lysate recovered after 1H-NMR spectroscopy was 
used for measurement of N-acetyl aspartic acid. The samples were prepared by 
adding 50µl of stable isotope internal standard solution containing 10µM N-acetyl 
aspartic acid-d3 and 10µl of 2% formic acid for acidification to 50µl of deproteinized 
tumour tissue lysate. 5µl of the sample thus prepared was injected into the HPLC 
tandem MS system. Stock standards of 1mM of N-acetyl aspartic acid and N-acetyl 
aspartic acid -d3 were prepared in deionized water. The calibration standards of 
respectively 1, 2, 5, 10 and 20 µM of N-acetyl aspartic acid were prepared by diluting 
the stock solution with deionized water.
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The HPLC-ms/ms system consisted of a Micromass Quattro LC connected to an 
Agilent HP1100 HPLC and a Gilson 232 XL autosampler. Using the autosampler 5µl 
aliquots of prepared sample were injected onto an Atlantis dC18 column (2.1mm X 
100mm, particle size 3µm). The mobile phase consisted of A: 0.3% formic acid in 
water and B: 0.3% formic acid in 50% methanol/water. NAA and NAA-d3 were 
(co-)eluted by running a (linear) step gradient; starting at 1% B at a flow rate of 250 
µl/min for 0.1 min, change to 100% B in 1.5 min. Column re-equilibration was 
initiated by increasing the flow rate to 280 µl/min in 0.1min, %B was kept at 100% 
for an additional minute and changed to 1% B in 0.1 min and kept at 1% B for 4.5 
min. The flow rate was then decreased to the initial value of 250 µl/min in 0.3 min. 
The total run-time was 7.3 min. The autosampler wash solvent was water.
 The HPLC flow was directed to a Quattro LC (Micromass) tandem mass 
spectrometer fitted with an electrospray ionization probe operated in positive 
mode at unit resolution. The capillary voltage was set at 1 kV and a cone voltage of 
14 V was used. The temperature settings for the source and ion block were 
respectively 400 ºC and 100 ºC. As a drying and nebulizing gas nitrogen was used 
at flow rates of respectively 650L/h and 100L/h. The collision cell was operated at 
10 eV with Argon as collision gas at a pressure of 0.18 Pa. 
 The mass spectrometer was set to monitor the ketene loss of both NAA and 
NAA-d3; recording the MRM mass transitions of m/z 176 to m/z 134 and m/z 179 to 
137 m/z, respectively.
 Quantification was performed using an area based linear regression curve 
derived from the stable isotope diluted calibration standards.
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Supplementary Figure 1  Comparison of succinate and NAA content in tumour tissues as 
determined by HPLC and 1H-NMR spectroscopy. Passing - Bablok regression plot to compare 
measurement of epinephrine and norepinephrine content in PGL tumour tissues by HPLC 
and 1H-NMR spectroscopy expressed as µg per mg tissue in Log10 scale.
Supplementary Figure 2  PCA analysis of purines in PGLs tumours. A: The PCA scores plot 
shows the first and second principle components and clearly discriminate between SDH, 
RET and NF1 tumours. B: The metabolites contributing to the maximum variances in 
principal components 1 and 2 are shown outside the circles and in the outer circle of the 
loading plot indicating that the concentrations of adenine, hypoxanthine and inosine 
cause the separation between RET and SDH tumours in the PCA score plot.
A B
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Supplementary Figure 3  Dot plot representing genotype specific differences in NAA/
Creatine ratio. Horizontal line represents the mean. Data sets having different alphabets 
above them are significantly different with data sets having the alphabet ‘b’ being the 
lowest (p<0.05).
Supplementary Figure 4  Dot plots representing genotype specific differences in NAA 
and Creatine. Horizontal line represents the mean. Data sets having different alphabets 
above them are significantly different with data sets having the alphabet ‘a-d’ in the 
ascending order for value, ‘a’ being lowest to ‘d’ being highest (p<0.05).
N-acetyl aspartic Acid Creatine 
b 
a a 
a, b, c 
c 
b, c 
b,d 
a,b,c,d 
a a, c 
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d 
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Supplementary Figure 5  PCA analysis of 1H NMR spectra of PPGLs with autoscaling. 
A: The PCA scores plot shows that the first and second principle components and clearly 
discriminate between SDH and RET tumours. B: The peak positions contributing to the 
maximum variances in principal components 1 and 2 are shown between the outer and 
inner circles of the loading plot.
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Abstract
Paragangliomas (PGLs) have widely different metastatic potentials. Two different 
types of PGLs can be defined by expression profiling. Cluster 1 PGLs exhibit VHL 
and/or succinate dehydrogenase (SDH) mutations, and a pseudohypoxic phenotype. 
RET and neurofibromatosis type 1 (NF1) mutations occur in cluster 2 tumors 
characterized by deregulation of the RAS/RAF/MAP kinase signaling cascade. 
Sporadic PGLs can exhibit either profile. During sustained hypoxia, a natural 
antisense transcript of hypoxia inducible factor 1 (aHIF) is expressed. The role of 
aHIF in the metastatic potential of PGL has not yet been investigated.
The aim was to test the hypothesis that genotype-specific overexpression of aHIF 
is associated with an increased metastatic potential. 
Tumor samples were collected from 87 patients with PGL. Quantitative PCR was 
performed for aHIF, VEGF, aquaporin 3, cytochrome b561, p57Kip2, slit homolog 3 and 
SDHC. Expression was related to mutation status, benign versus malignant 
tumors and metastasis free survival.
We found that both aHIF and VEGF were overexpressed in cluster 1 PGLs, and in 
metastatic tumors. In contrast, slit homolog 3, p57Kip2, cytochrome b561 and SDHC 
showed overexpression in non-metastatic tumors, whereas no such difference 
was observed for aquaporin 3. Patients with higher expression levels of aHIF and 
VEGF had a significantly decreased metastasis-free survival. Higher expression 
levels of SDHC are correlated with an increased metastasis-free survival. 
In conclusion, we not only demonstrate a higher expression of VEGF in cluster 1 
PGL, fitting a profile of pseudo-hypoxia and angiogenesis, but also of aHIF. 
Moreover, overexpression of aHIF and VEGF marks a higher metastatic potential 
in PGL.
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4.1  Introduction
Paragangliomas (PGLs) are catecholamine-producing tumors that originate from 
chromaffin cells of the adrenal medulla (pheochromocytoma proper) or from 
sympathetic neuronal tissue in extra-adrenal locations of the abdomen or chest 
(1). PGLs in the head and neck usually derive from parasympathetic tissues. 
Metastases occur in 10-15% of patients with PGL (2). 25-30% of the PGLs are caused 
by germline mutations of one of the susceptibility genes (3), i.e. the proto-oncogene 
RET and the tumor-suppressor genes von Hippel-Lindau (VHL), neurofibromatosis 
type 1 (NF1) or succinate dehydrogenase subunit A, B, C and D (SDHA/B/C/D) (4). 
Mutations in the VHL and/or SDH genes result in a phenotype known as 
pseudo-hypoxia (5,6), leading to uncontrolled expression of HIF-1α regulated 
genes, such as vascular endothelial growth factor (VEGF) which in turn facilitates 
angiogenesis (7)(7). The signature of hypoxia and angiogenesis is not limited to 
VHL and/or SDH-related tumors, but is also prominent in a subset of sporadic 
PGLs, as shown by tumor gene expression profiling (8). These ‘cluster 1’ tumors are 
distinct from ‘cluster 2’ tumors, which include RET and NF1-related and another 
subset of sporadic PGLs (8). This latter cluster is characterized by the deregulation 
of the RAS/RAF/MAP kinase signaling cascade. 
 High expression of HIF-1α and VEGF is associated with higher tumor 
aggressiveness and an unfavorable prognosis in many types of solid cancers 
(9,10). Hypoxia initially induces increased expression of HIF-1α, but during 
sustained hypoxia, the amount of HIF-1α mRNA is reduced (11). Instead, there is 
considerable overexpression of the HIF-1α natural antisense transcript (aHIF), 
which encodes the antisense template of the 3’ untranslated region of HIF-1α 
mRNA (12). This represents a negative feedback loop, in which aHIF inhibits the 
translation of HIF-1α mRNA after chronic hypoxia (13). A 20% of the human 
genome consists of these naturally occurring antisense transcripts, which 
regulate gene transcription, RNA splicing, polyadenylation, editing, stability, 
transport and translation (14-16). Importantly, besides acting as a transcription 
factor for hypoxia inducible genes, HIF-1α also stabilizes the tumor suppressor 
gene p53 under early hypoxic conditions (17). This situation is reversed during 
later stages of hypoxia, when HIF-1α translation is inhibited by aHIF (13), resulting 
in the loss of p53 followed by deregulated cell proliferation. Thus, aHIF expression 
also allows tumor cells to survive hypoxia without inducing the tumor suppressor 
p53 (12). Theoretically, aHIF expression is not mainly a phenotypical sign of chronic 
hypoxia, but also in itself mechanistically associated with more aggressive tumor 
behavior and increased metastatic potential (18). 
 So far, the role of aHIF in the pathophysiology of PGL had not been investigated. 
We hypothesize that there is a genotype-specific overexpression of aHIF expression 
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in PGL, which is associated with an increased metastatic potential. To test this 
hypothesis, we performed quantitative RT-PCR of aHIF and other cluster-specific 
genes (VEGF, aquaporin 3, cytochrome b561, p57Kip2, slit homolog 3 and SDHC) in 
PGLs of different genotypes and investigated the relation between expression of 
these genes and metastasis-free survival (8).
4.2  Materials and methods
Patients
Totally, 151 patients with histologically proven pheochromocytoma or extra- 
adrenal sympathetic PGL evaluated at the Departments of Endocrinology and 
General Internal Medicine at the Radboud University Nijmegen Medical Centre 
(RUNMC) underwent surgical resection of primary PGL between November 1967 
and November 2008.
 Details on the post-surgical follow-up of part of this cohort were published 
elsewhere (Timmers et al. 2008). Frozen primary tumor tissue was available from 
87 patients (41 males, 46 females), 5 of whom underwent surgery at the Erasmus 
MC in Rotterdam. Tumors were adrenal in 76 cases and extra-adrenal abdominal 
in 11 cases. The presence of germline mutations and large deletions of RET, VHL, 
NF1 and SDHB/C/D was investigated at the Department of Genome Diagnostics of 
the University Medical Centre in Utrecht according to standard procedures. 
Clinical characteristics and genotypes are listed in Table 1. In 44 patients with an 
apparently sporadic presentation, i.e. no family history and lack of syndromal 
features, full germline testing of all susceptibility genes was omitted. In these 
cases, SDHB immunostaining was carried out on tumor tissues to investigate the 
functional integrity of SDH (see below). Mutations in SDHB, SDHC or SDHD genes 
lead to lack of SDHB immunoreactivity and thus can be used to reveal germline 
mutations in these genes (van Nederveen et al., 2009). 
 During a mean±SD follow-up of 7.04 ± 5.07 (range: 0.05–20.83) years, 7 (8%) 
developed metastatic disease (Table 2). The mean ± SD interval between surgery 
and the diagnosis of metastases was 5.50 ± 8.15 (range: 0.00 – 19.38) years. Sixteen 
patients died, including 5 with metastatic PGL. Data were collected under 
conditions of regular clinical care, with the approval of ethics committee obtained 
for the use of those data for scientific purposes.
SDHB Immunohistochemistry
Of the 44 patients with apparently sporadic presentation, immunohistochemistry 
was performed in 37 patients to detect the expression of SDHB. Sections (4 µm) 
from paraffin-embedded tumor tissues were stained as described previously (van 
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Nederveen et al., 2009) using an anti-human rabbit polyclonal primary antibody 
(Sigma-Aldrich, St. Louis, MO, USA, HPA002868, 1:200).
Table 1   Clinical characteristics of paraganglioma (PGL) patients
Variable PGL patients (n=87)
Age (years)
Diagnosis mean ± SD 46.05 ± 16.17
Diagnosis range 7 – 77
Gender
Male 41
Female 46
Primary tumor location
Adrenal 76
Extra-adrenal 11
Tumor size (cm)
Mean ± SD 6.40 ± 3.42
Range 1.4 – 18 
Genotype
SDHB 3
SDHD 1
VHL 3
MEN2A 10
MEN2B 1
NF1 7
Sporadic* 18 (16 adrenal, 2 extra-adrenal)
Apparently sporadic 44 (39 adrenal, 5 extra-adrenal; 37/37 SDH-negativeb)
Total follow-up (years)
Mean ± SD 7.04  ± 5.07
Range 0.05 – 20.83
Metastases
No 80
Yes 7
a. SDHB, SDHC, SDHD, and MEN2 mutations and large deletions ruled out germline testing.
b. As assessed by positive SDHB immunohistochemistry
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Tumor tissue processing 
Representative snap frozen tumor samples were cut in approximately five sections 
of 20 µm in a cryostat at -20°C, put in lysis buffer (RLT, Qiagen, Hilden, Germany) 
and stored at -80 °C until RNA isolation. For histological confirmation, additional 
slices were H&E stained for histological re-evaluation by a pathologist.
RNA extraction
Total RNA was extracted using the RNeasy Mini Kit (Qiagen) with on-column 
DNase-I treatment. RNA concentrations were determined by measuring the 
 spectrophotometric absorption at 260 nm using the GeneQuant (Amersham, 
Eindhoven, The Netherlands). 
 
RT reaction
cDNA synthesis was performed using 10 µl sample volume, containing approximately 
1 µg total RNA and 10 µl RT-mix, with a total volume of 20 µl. cDNA synthesis 
was performed using a PTC-200 PCR apparatus (MJ Research). Samples were 
denatured for 10 minutes at 70°C and immediately cooled on ice. After random 
hexamers were annealed for 10 minutes at 21 °C, cDNA synthesis was performed 
for 45 minutes at 42 °C, followed by an enzyme inactivation step for 5 minutes 
at 99 °C. 
Quantitative PCR
For the quantitative PCR (qPCR), SYBR Green assays were used for aHIF and VEGF, 
and Taqman for aquaporin 3 (Gill blood group), cytochrome b561, p57Kip2, slit 
homolog 3 (Drosophila melanogaster) and SDHC. The latter 5 genes were selected 
because in a previous study by Dahia et al. (8), their RNA expression was shown to 
mark either cluster 1 or 2 PGL. Overexpression of VEGF and aquaporin 3 mark 
cluster 1 tumors, whereas Cytochrome b561, P57Kip2, Slit homolog 3 and SDHC 
mark cluster 2 tumors. qPCR was performed using the Taqman Universal PCR 
Master Mix or SYBR Green Universal Master Mix (PE Applied Biosystems, 
Nieuwerkerk aan den IJssel, The Netherlands) in a total volume of 25 µl. The 
forward and reverse primers, as well as the optimal concentrations (for each 
target gene), were optimized in previous studies at the Department of Laboratory 
Medicine of the RUNMC for the SYBR Green assays, whereas Assays on Demand 
(PE Applied Biosystems) was used for the Taqman based assays. Hypoxan-
thine-guanine phosphoribosyltransferase (HPRT1) was used as a housekeeping 
gene for normalization of all samples (19). qPCR was performed using the ABI 
Prism 7700 Sequence Detector (PE Applied Biosystems). The amplification 
reactions were carried out with denaturation at 95°C for 10 min, 40 cycles of 15 s at 
95°C (melting) and 60 s at 60°C (annealing and elongation). 
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Statistical analysis
Statistical analysis was performed using Statistical Package for the Social Sciences 
(for Windows 16.0; SPSS 16.0, Chicago, IL, USA). Aquaporin-3 mRNA levels were 
normally distributed (one-sample Kolmogorov-Smirnov), whereas those of other 
genes were not. After log-transformation a normal distribution of mRNA expression 
was found for the other genes. Thus, parametric tests were used for all the log- 
transformed mRNA levels, with the exception of Aquaporin-3, which was already 
normally distributed before log-transformation. Analysis of Variance (ANOVA) with 
post-hoc Tukey HSD test was used to test for the differences in mRNA expression of 
the target genes between cluster 1 and 2 PGLs, sporadic PGLs and apparently sporadic 
PGLs with unknown genotype. Differences in the mRNA expression between 
metastatic and non-metastatic tumors were tested using an independent samples 
t-test. In addition, the relation between expression of individual genes and meta-
stasis-free survival was investigated. Normalized mRNA levels of an individual 
target gene were correlated with metastasis-free survival after dichotomizing on 
the basis of the median mRNA expression of individual genes using univariate Cox 
regression survival analysis. Metastasis-free survival of patients with an above 
versus below median expression was compared using the Kaplan Meier method, 
and a log-rank test for equality of survival distributions. A similar analysis was 
performed for overall survival.
4.3  Results
SDHB expression in apparently sporadic tumor tissues
Presence of SDHB immunoreactivity and a granular staining pattern typical of 
mitochondrial proteins was detected in all the tumor tissues of apparently 
sporadic cases. This includes the four metastatic cases with incomplete germline 
mutation testing (supplementary figure). 
Genotype-specific mRNA expression
Figure 1 illustrates differences in mRNA expression of the individual target genes 
between sporadic PGLs (n = 18), apparently sporadic PGLs (n = 44), and cluster 1 
PGLs (SDHB (n = 3), SDHD (n = 1), VHL (n = 3)) and cluster 2 PGLs (MEN2A (n = 10), 
MEN2B (n = 1), NF1 (n = 7)). After performing an ANOVA with post-hoc Tukey HSD 
test to compare mRNA expression of individual genes, both VEGF (figure 1A) and 
aHIF (figure 1B) expression was found to be significantly higher in cluster 1 as 
compared to cluster 2 PGLs (P = 0.018 and P = 0.021, respectively). Sporadic and 
apparently sporadic tumors exhibited expression levels that were not significantly 
different from cluster 1 and cluster 2 tumors. No differences were found in 
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aquaporin 3, cytochrome b561, p57Kip2, slit homolog 3 or SDHC expression (not 
shown). 
To further explore the significantly higher expression of VEGF and aHIF in cluster 1 
compared to cluster 2 PGLs, genotype-specific mRNA expression levels are shown 
in figure 2. SDHB, SDHD and VHL (cluster 1) tumors on average exhibit higher 
expression levels for both aHIF and VEGF than MEN2A, MEN2B and NF1 (cluster 2) 
related tumors. The size of the subgroups precluded relevant statistical analyses.
mRNA expression and metastasis-free survival 
The mRNA expression of each gene in non-metastatic PGLs (n = 80) versus the 
mRNA expression in the primary tumors of metastatic PGLs (n = 7) is visualized in 
figure 3. The RNA expression of both VEGF (P = 0.001) and aHIF (P = 0.001) was 
significantly higher in the primary tumors of PGLs that metastasized during 
follow up, than in non-metastatic PGLs (figure 3a-b). Aquaporin 3 expression was 
not significantly different between groups (figure 3c), whereas the expression of 
slit homolog 3 (P = 0.019), p57KIP2 (P = 0.035), cytochrome b561 (P = 0.003) and 
SDHC (P = 0.039) was significantly higher in the non-metastatic group than in the 
metastatic group (figure 3d-g). 
 Subsequently, we assessed whether metastasis-free survival differed between 
the groups of patients after dichotomization at the median expression level using 
a Kaplan-Meier analysis with log-rank testing. This analysis indicates that high 
Figure 1  Box and whiskers plots (box= median with 25th and 75th percentile, and whiskers 
are minimum and maximum values) of log normalized expression levels of VEGF (A) and 
aHIF (B) in sporadic, apparently sporadic, and cluster 1 or cluster 2 type of PGLs. Significant 
differences, as assessed by ANOVA and post-hoc Tukey HSD testing, were found only 
between cluster 1 and cluster 2 tumors.
A B
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expression of VEGF is associated with decreased metastasis-free survival (figure 4a, 
P = 0.004). This is also true for high aHIF expression (Figure 4b, P = 0.011). Among 
the seven metastatic cases, high VEGF and aHIF expression did not seem to 
correlate with (metastasis-free) survival (data not shown). An opposite effect was 
observed for SDHC expression (P = 0.008) (figure 4g). For the other genes, metasta-
sis-free survival was not significantly different between the high versus low 
expression groups, although low levels of expression were without exception 
associated with poor prognosis. Overall survival was not significantly different 
between the high versus low expression groups, although there was trend 
towards a higher mortality in patients with high VEGF expression (P = 0.067, data 
not shown).
Discussion
This is the first study in which the role of the natural antisense transcript aHIF is 
investigated in PGL. We found that aHIF, along with VEGF, is overexpressed in 
PGLs with a pseudohypoxic signature due to SDH and VHL mutations. Over- 
expression of both factors is also associated with a decreased metastasis-free 
survival, marking an increased malignant potential of apparently benign primary 
PGLs. Conversely, slit homolog 3, p57Kip2, cytochrome b561 and SDHC showed 
overexpression in non-metastatic tumors, whereas no difference was observed 
for aquaporin 3. Higher expression levels of SDHC are correlated with an increased 
 metastasis-free survival. 
Figure 2  Box and whiskers plots (box= median with 25th and 75th percentile, and whiskers 
are minimum and maximum values) of log normalized expression levels of VEGF (A) and 
aHIF (B) in sporadic, apparently sporadic, and PGLs defined by specific genotype.
A B
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 HIF-1α regulates the transcription of a number of genes that are known to 
be involved in tumorigenesis and angiogenesis (20), including VEGF (21). In VHL 
disease, stabilization of HIF-1α in PGL tumor cells is the result of decreased 
pVHL-dependent proteosomal degradation of HIF-1α by the E3 ubiquitin ligase 
Figure 3  Box and whiskers plots (box= median with 25th and 75th percentile, and whiskers 
are minimum and maximum values) of expression levels of VEGF (A), aHIF (B), Aquaporin-3 
(C), SLIT3 (D), KIP2 (E), Cytochrome b561 (F) and SDHC (G) between non-metastatic and 
metastatic PGL tumors. Significances are for Student’s t-testing of normalized values.
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complex, after being hydroxylated by prolyl hydroxylase (6). In case of underlying 
mutations of the mitochondrial enzyme SDH, succinate accumulation inhibits 
prolyl hydroxylase activity and consequently HIFα  stabilization (20). As shown in 
Figure 4  Kaplan-Meier plots of metastasis free survival in PGL patients dichotomized by 
the mean tumor expression level of VEGF (A), aHIF (B), Aquaporin-3 (C), SLIT3 (D), KIP2 (E), 
Cytochrome b561 (F) or SDHC (G). Straight lines > median, dashed lines < median. 
Significances are for log-rank testing.
A
C
E
G
B
D
F
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SDHA, B and D-associated PGL, abolishment of SDH activity results in over- 
expression of VEGF, a target gene of HIF-1α (5,22,23). Mitochondrial dysfunction 
due to SDH-mutations and activation of the hypoxic pathway is probably 
interlinked with other mechanisms of tumorigenesis involving oxidative stress 
and apoptosis resistance (24). Reactive oxygen species were shown to inhibit the 
action of prolyl hydroxylase, thereby increasing HIF-1α and VEGF availability (25). 
Another important theory interlinking the pathogenesis of different hereditary 
forms of PGL pertains to the developmental culling of sympathetic neuronal 
precursor cells by affecting c-Jun-dependent neuronal apoptosis following 
withdrawal of neuronal growth factor (26).The role of hypoxia and angiogenesis 
as a pathophysiological mechanism in a subset of PGLs was confirmed by gene 
expression profiling studies by Dahia and coworkers (8). PGLs caused by germline 
VHL and SDH mutations exhibit a clear signature of (pseudo) hypoxia and 
angiogenesis, assigned as ‘cluster 1’ tumors. On the other hand, RET and NF1 related 
PGLs, so-called cluster 2 tumors, are characterized by a deregulated RAS/RAF/
MAP kinase signaling cascade which is associated with metabolism, translation 
initiation and RNA/protein synthesis. Subsets of sporadic tumors were shown to 
fit either the cluster 1 or 2 profile. Our current findings of overexpression of VEGF 
in cluster 1 tumors and corroborate these previous findings. The expression of 
other genes that were suggested to be cluster-related, i.e. p57Kip2, slit homolog 3, 
aquaporin 3, Cytochrome b561 and SDHC, was not significantly different between 
the groups in our study.
 Besides by factors mentioned above, the expression of HIF-1α is also regulated 
by aHIF, a naturally occurring antisense transcript RNA that forms a double 
stranded RNA molecule with the antisense transcript of HIF-1α (12,13). Naturally 
occurring antisense transcript expression can lead to the down-regulation of the 
sense transcript by RNA interference (14,16). Naturally occurring antisense 
transcript RNAs also exhibit important biological functions in DNA methylation 
(27), genomic imprinting (28), X-chromosome inactivation (29), genomic 
recombination (30), and RNA splicing, polyadenylation, editing, stability, 
transport and translation (31) (32). In vitro experiments in renal cell carcinoma 
cells have yielded insight in the oxygen-dependent regulation of HIF-1α (12,13). 
Hypoxic conditions initially induce overexpression of HIF-1α. During sustained 
hypoxia, however, HIF-1α mRNA decreases in parallel with increased expression 
of aHIF, suggesting inhibition of HIF-1α by aHIF through a negative feedback loop. 
Our current finding of increased aHIF expression in parallel with VEGF in SDH- 
and VHL-related PGL fits a pattern of a chronic (pseudo-) hypoxic state. This 
suggests that aHIF can serve as a surrogate marker of chronic HIF-1α activation, 
taking into account that measurement of the HIF-1α protein itself is cumbersome. 
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Besides its involvement in hypoxia-related tumorigenesis, HIF-1α stabilizes the 
tumor suppressor gene p53 (17). Inhibition of HIF-1α by aHIF during sustained 
hypoxia results in the loss of p53 and subsequent tumor cell proliferation (13). This 
aHIF-mediated escape from p53-mediated apoptosis theoretically translates into 
more aggressive tumor behavior and increased metastatic potential. Over- 
expression of aHIF has been clearly established in malignant non-papillary clear 
cell renal carcinoma (12). In breast cancer, overexpression of aHIF was shown to be 
a marker of poor prognosis (18). In the present study, aHIF expression in primary 
tumors turned out to be a predictor of decreased metastasis-free survival. There 
are currently no reliable histological criteria for malignant PGL besides the 
presence of metastatic lesions in locations where chromaffin tissue is normally 
absent (33). The 5-year survival of patients with metastatic PGL is approximately 
50% (34,35), and no cure is available. It is therefore critical to identify biomarkers 
of malignancy such as aHIF. Besides aHIF, VEGF was also negatively correlated 
with metastasis-free survival.  High expression of Cytochrome b561, p57Kip2, slit 
homolog 3 and SDHC on the other hand was associated with a benign course. 
These expression profiles of malignant PGL fit those of cluster 1 tumors. Among 
cluster 1 tumors, specifically SDHB mutations are strongly associated with a 
malignant course, whereas VHL- and SDHD-related PGLs are rarely malignant. 
Our findings, however, probably do not specifically reflect the SDHB genotype, 
since only two out of seven patients who developed metastases were known 
mutation carriers. However, considering the low frequency of malignancy in 
VHL/SDHD-related tumors, a cluster 1 signature of hypoxia/angiogenesis along 
with increased aHIF and VEGF expression as observed in our VHL and SDHD 
samples does not automatically translate into a high malignant potential. The 
discrepancy in metastatic potential between cluster 1 tumors of different 
genotypes suggests that other pathophysiological mechanisms besides hypoxia/
angiogenesis are involved. Also, we emphasize that the expression of aHIF is 
highly variable, so it cannot be used as a marker of malignancy in individual 
patients. It is likely that individual risks of developing metastases can only be 
estimated by use of a combination of clinical, biochemical, genetic and molecular 
markers (36,37). In this context, protein expression of SNAIL, a zinc-finger 
transcription factor, has been identified as a useful marker of metastatic potential 
of PGL (38).
 Our current study has several limitations. The study includes a limited 
number of patients with metastatic disease. The role of aHIF as a predictor of 
malignancy needs to be further evaluated in a larger cohort with a longer 
follow-up. Also, the role of aHIF as a marker of the up-regulation of hypoxic and 
angiogenic pathways in the tumorigenesis of PGL needs further exploration 
across tumors of different genotypes, specifically SDHB versus other cluster 1 
78
genotypes. Since the samples that we investigated spanned several decades, the 
integrity of mRNA could theoretically have decreased over time in the older 
samples. We did, however, not find such a correlation for aHIF expression. Formal 
genetic testing was omitted in several patients with apparently sporadic PGL, i.e. 
in those with a negative family history and lack of syndromal features. In these 
cases, SDHB immunostaining was used as ‘surrogate’ genotyping. The sensitivity 
and specificity of this approach awaits prospective evaluation. In conclusion, 
along with VEGF, the expression of aHIF, a naturally occurring antisense transcript 
of HIF-1α, is increased in cluster 1 PGL, fitting a profile of pseudo-hypoxia and 
angiogenesis. Moreover, overexpression of aHIF and VEGF marks a higher 
metastatic potential in PGL.
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Supplementary Figure 1  SDHB immunostaining in pheochromocytoma tumor tissues 
from patients with metastatic disease. Panel A: 58 year old male (Table 2), right adrenal PGL. 
Panel B: 40 year old male (Table 2), left adrenal PGL. An image of higher magnification (20X) 
is enclosed in the inset. Note: Strong granular staining pattern in the tumor cells.
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Abstract
Pheochromocytomas and paragangliomas (PPGLs) can be localized by 18F-FDG 
PET. The uptake is particularly high in tumours with an underlying succinate 
dehydrogenase (SDH) mutation. The latter are characterized by compromised 
oxidative phosphorylation and a pseudo-hypoxic response which mediates an 
increase in aerobic glycolysis, also known as the Warburg effect. The aim of this 
study was to explore the hypothesis that increased uptake of 18F-FDG in 
SDHx-related PPGLs is reflective of increased glycolytic activity and is correlated 
with expression of different proteins involved in glucose uptake and metabolism 
through the glycolytic pathway.
Methods: Twenty-seven PPGLs collected from patients with hereditary mutations 
in SDHB (n=2), SDHD (n=3), RET (n=5), NF1 (n=1), MAX (n=1) and sporadic patients 
(n=15) were investigated. Pre-operative 18F-FDG PET/CT studies were analyzed; 
mean and maximum standardized uptake values (SUVs) in manually drawn 
regions of interest were calculated. Expression of proteins involved in glucose 
uptake (GLUT-1 and 3), phosphorylation (HK-1, 2 and 3), glycolysis (MCT-4) and 
angiogenesis (VEGF, CD34) were examined in paraffin-embedded tumour tissues 
using immunohistochemical staining with peroxidase-catalyzed polymerization 
of diaminobenzidine as read-out. Expression was correlated with corresponding 
SUVs.
Results: Both maximum and mean SUVs for SDHx-related tumours were 
significantly higher than for sporadic and other hereditary tumours (P<0.01). The 
expression of HK-2 and HK-3 were significantly higher in SDHx-related PPGLs 
compared to sporadic PPGLs (P=0.022, P=0.025). The expression of HK-2 and VEGF 
were significantly higher in SDHx-related PPGLs compared to other hereditary 
PPGLs (P=0.039, P=0.008). No statistical differences in the expression were 
observed for GLUT-1, GLUT-3 and MCT-4. Percentage anti-CD 34 staining and mean 
vessel perimeter were significantly higher in SDHx-related PPGLs compared to 
sporadic tumours (P=0.050, P=0.010). Mean SUVs significantly correlated with 
the expression of HK-2 (P=0.027), HK-3 (P=0.013), VEGF (P=0.049) and MCT-4 
(P=0.020). 
Conclusion: Activation of aerobic glycolysis in SDHx-related PPGLs results in 
increased 18F-FDG accumulation and is associated with accelerated glucose phos-
phorylation by hexokinases rather than increased expression of glucose 
transporters.
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5.1  Introduction
Pheochromocytomas and paragangliomas (PPGLs) are catecholamine-producing 
neuroendocrine tumours arising from the chromaffin cells of the adrenal medulla 
and extra-adrenal sympathetic paraganglia. PPGLs can occur as part of hereditary 
syndromes. Susceptibility genes include succinate dehydrogenase (SDH) complex 
subunits and assembly factor 2 (SDHA/B/C/D/AF2), von Hippel-Lindau (VHL), 
RET, neurofibromatosis (NF) 1, myc-associated factor X (MAX) and transmembrane 
protein 127 (TMEM127) (1). Gene expression profiling has revealed the presence of 
two clusters of PPGLs: cluster 1 (VHL, SDHx) which show increased expression of 
genes associated with angiogenesis and hypoxia whereas cluster 2 (RET, NF1, 
TMEM127 and MAX) display a rich signature of RNA synthesis and kinase signaling 
(2,3).
 Enhanced uptake of glucose by tumour cells compared to normal cells is the 
hallmark of in vivo cancer imaging with 18F-fluorodeoxyglucose positron emission 
computed tomography (18F-FDG PET/CT). We have shown previously that 18F-FDG 
PET/CT is superior to other functional imaging techniques for localizing metastatic 
PPGL, particularly in those with an underlying SDHB mutation (4-6). 18F-FDG PET/CT 
is also very useful for localizing benign PPGLs (7). Interestingly, 18F-FDG uptake varies 
among PPGLs of different genotypes, with the highest standard uptake values 
(SUVs) being observed in SDH and VHL-related tumours (5,8). The precise mechanism 
behind these genotype-specific differences in 18F-FDG uptake has not been elucidated.
 SDHx mutations cause impairment of SDH function in the mitochondrial 
electron transport chain and hence compromise oxidative phosphorylation 
(9-11). Abolition of SDH enzymatic activity results in activation of the hypoxic- 
angiogenic pathway via transcription factor hypoxia-inducible factors (HIFs)-1α 
and -2α (12). Their main target genes include genes involved in glucose metabolism 
(glucose transporters (GLUT), hexokinases (HK), angiogenesis (vascular endothelial 
growth factor (VEGF)), survival and motility (13-15). Activation of HIF-α further 
supports the shift of tumour cell energy metabolism from oxidative phosphoryla-
tion towards aerobic glycolysis, also known as the Warburg effect (16). The 
alternative energy generation pathway is somewhat less efficient requiring a 
much larger cellular influx of glucose to maintain tumour cells energy needs. 
 High uptake of 18F-FDG by SDHx-related tumours has been suggested to be a 
reflection of the Warburg effect. Various mechanisms for accelerated glucose use 
by tumour cells have been described. Enhanced influx of glucose via glucose 
transporters (GLUTs) is considered to be the most important. Overexpression of 
GLUT isoforms GLUT-1 and 3 is closely related to 18F-FDG uptake in tumour cells 
(17). In addition, accelerated glucose phosphorylation by the cytosolic enzyme 
hexokinase (HK) as the first step toward glycolysis results in enhanced 18F-FDG 
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accumulation. HK-2 is predominantly expressed in tumour cells that exhibit the 
Warburg effect (18) and is associated with elevated 18F-FDG uptake in malignant 
conditions (19,20). Upregulation of both GLUTs and HK is frequently associated 
with malignant transformation of cells (21). Furthermore, activity of HK-3 and 
monocarboxylate transporter type 4 (MCT-4), which facilitates the cellular lactate 
transport, possibly are regulated by hypoxia (10,22). In addition, hypoxia also 
promotes anaerobic glycolysis and several studies have demonstrated that 18F-FDG 
uptake is an indirect reflection of tumour hypoxia (23,24). 
 The aim of this study was to explore the hypothesis that increased uptake of 
18F-FDG is reflective of increased glycolytic activity and is correlated with 
expression of different proteins involved in glucose uptake and metabolism 
through the glycolytic pathway. Therefore, immunohistochemical expression of 
GLUT-1, GLUT-3, HK-1, HK-2, HK-3 and MCT-4 was directly correlated with in vivo 
18F-FDG uptake in PPGLs of different genotypes. Additionally, VEGF expression 
was examined to account for hypoxia regulated angiogenesis, and also CD34 to 
account for genotype-specific differences in microvasculature that could alter the 
radiotracer supply to tumour cells.
5.2  Materials and methods 
Patients
The study included 27 consecutive patients (17 men and 10 women, aged [mean±SD] 
51±15 years) in whom PPGL was histopathologically confirmed and of which 22 
(81%) were adrenal and 5 (19%) extra-adrenal in location. Patient characteristics 
are listed in (supplementary) Table 1. The institutional review board approved this 
retrospective study and the requirement to obtain informed consent was waived.
18F-FDG PET/CT Scanning
All patients underwent pre-surgical evaluation with 18F-FDG-PET/CT at the 
Radboud University Medical Center between December 2007 and February 2012 
(Figure 1). Patients fasted for at least 6 hours before receiving a [mean±SD] 241±73 
Mbq dose of intravenous 18F-FDG based on body weight. PET/CT scans were 
performed ~one hour (range; 55–74 minutes) after injection. Before November 
2011, imaging was performed using a Biograph 2 PET/CT, and after November 2011 
using an mCT-40 scanner (both Siemens Healthcare, USA). Both scanners were 
calibrated and certified by European Association of Nuclear Medicine (EANM) 
Research Ltd (EARL) in accordance with the EANM guidelines for PET/CT (25). First, 
a low-dose CT scan using “CareDose” with reference 40 mA and 130 kV was 
performed from the base of the skull to the mid-thigh. Instructions for breathing 
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and positioning were given to patients. The CT transaxial matrix size was 512 x 512 
with pixels of 0.98 x 0.98 mm2 for both scanners. CT slice width was 3 mm for the 
Biograph 2 and 1.5 mm for the mCT. PET images were obtained using OSEM2D 
reconstruction on the Biograph 2 with 4 iterations and 16 subsets and a post 
reconstruction Gaussian filter of 5 mm FWHM. Transaxial PET matrix size was 
128x128 and pixel size was 5.31 x 5.31 x 3 mm3. For the mCT, images were obtained 
using time-of-flight and HD reconstruction with 3 iterations and 21 subsets and a 
post reconstruction Gaussian filter of 8 mm FWHM. Transaxial PET matrix size 
was 256x256 and pixel size was 3.18 x 3.18 x 3 mm3. The large value of the Gaussian 
filter for the mCT images resulted in additional smoothing and was used in order 
to comply with the EANM guidelines for PET CT (25) allowing direct comparison 
of quantitative data from both scanners.
Image Interpretation and Quantitative Measurements
PET/CT images were reviewed using Inveon Research Workplace version 4.1 
software (Siemens Healthcare). Regions of interest (ROI) were manually drawn in 
each transversal slice over visually assessed lesions in correspondence with CT 
images. ROIs were combined to form a volume of interest (VOI), which was used 
for quantitative analysis. Maximum and mean standardized uptake values 
(SUVs) normalized for body weights were calculated as SUV = A / IA x BW [A: 
activity concentration of VOI (Bq/ml), BW: body weight (g), IA: injected activity 
(Bq)]. Liver-normalized SUVs were calculated as PPGL SUVs divided by 
corresponding liver mean SUVs in a fixed volume of interest in the upper central 
Table 1   Patients characteristics
Genotype N  
(patients)
Gender Age,  
years 
Tumour location Tumour 
dimensions,  
cm3
M F A EA
Sporadic* 15 8 7 54.2 ± 14.9 14 1 47.9 ± 56.3
SDHB 2 2 0 31.0 ± 14.1 0 2 3.4 ± 2.4
SDHD 3 2 1 49.5 ± 13.4 1 2 26.0 ± 33.8
MEN-2 5 4 1 46.8 ± 14.4 5 0 14.8 ± 21.0
NF1 1 0 1 70 1 0 51.7
MAX 1 1 0 63 1 0 20.4
*Presence of germline mutations and large deletions in SDHB/C/D, RET, VHL, and—since 2011—in 
SHDA, SDHAF2, TMEM127, and MAX was investigated using standard procedures, and no mutation 
was detected.
Study included a total of 27 patients. Data are presented as mean ± SD.
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liver. All calculated SUVs were decay corrected by using the following formula: 
A0 = At x eλt [A0: corrected activity, At = uncorrected activity, λ = decay constant 
(ln2/110) min-1, t = elapsed time in min]. 
Immunohistochemical Staining and Quantification and 
Quantitative Polymerase Chain Reaction (qPCR)
See supplementary information for details.
Statistical Analysis 
Statistical analysis was conducted using SPSS 20 (SPSS Inc, Chicago, IL) and 
GraphPad Prism 6 software (Graphad Inc, La Jolla, CA). For comparison of immuno-
histochemical staining scores and SUVs of different genotypes, scores and 
SUVs were analyzed using Kruskal Wallis test with post-hoc Dunn’s test. 
Results are presented as mean ± SD. Correlations were examined using Spearman 
correlation test. A two-side P value less than 0.05 was considered to be statistically 
significant.
Figure 1  Imaging results in a patient with a sporadic PPGL located in the left adrenal. 
(A) 18F-fluorodeoxyglucose positron emission tomography (B) 123I-metaiodobenzylguanidine 
single photon emission tomography (C) Computed tomography scan.
A B  
C  
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5.3  Results
18F-FDG Uptake in PPGLs 
Maximum SUVs of PPGLs ranged from 0.8 to 11.8 (3.7 ± 3.2) and mean SUVs from 
0.6 to 5.4 (1.8 ± 1.5). The distribution of SUVs in PPGLs across hereditary and sporadic 
tumours is shown in Figure 2. The maximum SUV for hereditary cluster 1 tumours 
(SDHB, SDHD) was higher (9.6 ± 1.5) than for hereditary cluster 2 tumours (RET, NF1, 
MAX: 1.9 ± 0.3, P<0.01) and sporadic tumours (2.6 ± 1.7, P<0.01). Also, mean SUVs for 
hereditary cluster 1 tumours were higher (4.5 ± 0.8) than for hereditary cluster 2 
(1.0 ± 0.1, P<0.01) and sporadic tumours (1.3 ± 0.8, P<0.01).
 Maximum SUVs were higher for adrenal (2.7 ± 1.8, P<0.001) and extra-adrenal 
PPGLs (8.2 ± 4.3, P<0.01) than for normal adrenal glands (1.2 ± 0.5). Also, mean SUVs 
were higher for adrenal (1.3 ± 0.8, P<0.01) and extra-adrenal PPGL (4.0 ± 1.9, P<0.01) 
than for normal adrenal glands (0.8 ± 0.2). 18F-FDG uptake by normal adrenal 
glands did not exceed that of the liver in any case. No false-positive lesions were 
observed on 18F-FDG PET/CT. 
 The volume of the PPGL lesions were calculated as described before (26) and 
varied from 0.8 to 161 cm3 (35 ± 46). There was no significant relation between 
tumour volume and 18F-FDG uptake (P=0.945).
Figure 2  18F-fluorodeoxyglucose positron emission tomography standardized uptake value 
(SUV) in PPGLs across different genotypes. (A) Maximum SUV (B) Mean SUV. All SUVs are 
normalized for body weight and liver and corrected for decay. **P < 0.01.
A B
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Markers of Glucose Uptake and Metabolism
All 27 PPGL samples showed a positive cytoplasmic staining for HK-1. Staining 
was high across samples (Figure 3A) and no significant differences were observed 
between the different genotypes and sporadic samples (Figure 4). 
 HK-2 staining showed a clear variation between samples (Figure 3A). Negative 
to occasionally medium cytoplasmic staining was encountered in sporadic 
tumour samples. HK-2 expression was found to be significantly higher in 
SDHx-related PPGLs than in sporadic (P=0.022) and RET, NF-1 and MAX-related 
tumours (P=0.039) (Figure 4). Increased expression of HK-2 was confirmed at 
the mRNA level using qPCR and a high (P=0.004) expression of the markers 
was observed in SDHx-related tumours when compared to sporadic tumours 
and cluster 2-related tumours (supplementary Figure 1). HK-3 expression was 
significantly higher in SDHx-related PPGLs than in sporadic tumours (P=0.025), 
Figure 3  Immunohistochemical staining of PPGLs for hexokinases. Representative images 
of a SDHB, RET and sporadic tumour with magnifications as indicated. Areas with brown 
color (DAB polymer) are representative of positive staining.
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however when compared to RET, NF-1 and MAX-related tumours no statistical 
significance was observed (Figure 4).
 GLUT-1 and GLUT-3 showed predominantly cytoplasmic staining and 
occasionally (5-10%) cell membrane staining (Figure 3B). Sporadic, SDHx, RET, NF-1 
and MAX-related tumours showed an overall similar GLUT-1 expression (Figure 5). 
A homogeneous distribution of staining in the cytoplasm was observed. Sporadic 
and RET associated tumours showed a similar GLUT-3 expression, which was 
usually scored as medium. SDHx-related PPGLs appeared to exhibit a higher 
GLUT-3 staining compared to sporadic and RET PPGLs. However, statistical 
significance was not achieved (Figure 6). On the other hand, at the mRNA level, 
GLUT-3 expression did not show significant differences between the groups 
(supplementary Figure 1). MCT-4 was localized to cytoplasm as well as membrane. 
Figure 4  Comparison of staining for HK-1 (A), HK-2 (B), and HK-3 (C) among different PPGL 
genotypes. Graphs represent staining scores, calculated as percentage area stained positive 
times staining intensity. Groups with different letters as superscripts are significantly 
different.
A
B
C
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The expression of MCT-4 did not show significant differences between the 
different genotypes (Figures 3B and 6). VEGF expression was found to be significantly 
higher in SDHx-related PPGLs compared to RET, NF-1 and MAX-related PPGLs 
(P=0.008) (Figure 3C and 6). There was a significant difference in mean percentage 
anti-CD34 stained area (P=0.050) and mean vessel perimeter (P=0.010) between 
SDHx-related and sporadic PPGLs. The microvessel density did not differ among 
genotypes.
Relationship between 18F-FDG Uptake and Markers of Glucose 
Uptake and Metabolism
The correlative relationships between immunohistochemical staining and 
calculated SUVs and corresponding P-values are summarized in Table 2. Mean 
SUVs of PPGLs were significantly associated with HK-2, HK-3, VEGF and MCT-4 
staining. The strongest correlation with SUV was found for HK-3 expression 
(R=0.471, P=0.013). No significant relationship was found between GLUT-1 and 
GLUT-3 staining and SUV. Maximum SUVs showed only a significantly correlative 
relationship for HK-2 (R=0.409, P=0.034) and HK-3 immunohistochemical staining 
Figure 6  Comparison of staining for GLUT-1 (A), GLUT-3 (B), VEGF (C), and MCT-4 (D) among 
different PPGL genotypes. Graphs represent staining scores, calculated as percentage area 
stained positive times staining intensity. Groups with different letters as superscripts are 
significantly different.
A
C
B
D
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(R=0.381, P=0.050). No correlative relationships were found for 18F-FDG uptake and 
vessel parameters.
5.4  Discussion
We examined the ex vivo expression of markers of the Warburg effect in PPGLs 
using immunohistochemical staining and their correlation with uptake of in 
vivo 18F-FDG on PET/CT scans. We confirmed genotype-specific differences in 
18F-FDG uptake where SDHx-related PPGLs showed highest SUVs. The expression of 
HK-2 was significantly higher in SDHx-related PPGLs compared to sporadic and 
cluster 2 PPGLs. Furthermore, expression of HK-3 was significantly higher in 
SDHx-related PPGLs compared to sporadic PPGLs and expression of VEGF was 
significantly higher in SDHx-related PPGLs compared to cluster 2 PPGLs. Uptake of 
18F-FDG significantly correlated with the expression of HK-2, HK-3, VEGF and 
MCT-4.
 Similar to glucose, 18F-FDG is taken up by tumour cells mostly via facilitative 
transport by GLUTs. After cell entry, 18F-FDG is phosphorylated by HKs into 
18F-FDG-6-P which, in contrast to glucose-6-P, cannot be further metabolized 
along the glycolytic pathway. The cell membrane is impermeable to 18F-FDG-6P so 
it accumulates within cells directly proportionate to their metabolic activity. 
18F-FDG-6P can theoretically escape from the cell by dephosphorylation back to 
Table 2   Correlations between 18F-fluorodeoxyglucose uptake and immuno-
histochemical markers of glucose uptake and metabolism
Marker SUV Maximum SUV Mean
R P R P
HK-2 0.409 (0.034)* 0.425 (0.027)*
HK-3 0.381 (0.050)* 0.471 (0.013)*
GLUT-1 -0.001 (0.998) -0.100 (0.620)
GLUT-3 0.174 (0.386) 0.263 (0.185)
VEGF 0.312 (0.114) 0.383 (0.049)*
MCT-4 0.373 (0.055) 0,444 (0.020)*
All SUVs are normalized to liver normalized and decay corrected. Correlations are expressed as 
Spearman’s rho and P-value (* = P < 0.05). 
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18F-FDG by glucose-6-phosphatase. In general, this process is negligible because of 
the low intracellular levels of the dephosphorylating enzyme.  Therefore, 18F-FDG 
uptake of any cell is determined by expression of GLUTs and activity of HKs. 
Another possible determinant is tumoural blood flow which brings 18F-FDG to the 
cell and reasonably increases its metabolism in parallel. However, activation of 
the hypoxic-angiogenic pathway via HIF-1α and -2α results in adaptation of the 
tumour to a hypoxic environment and consequently an uncoupling of blood flow 
and metabolism implying hypoxic stimulation of glucose metabolism in the 
presence of adequate oxygen. This phenomenon, known as the Warburg effect 
(27), characterizes cluster 1 PPGLs (VHL, SDHx). Favier et al. demonstrated that 
HIF-2α, which together with HIF-1α upregulates VEGF and GLUT-1 gene expression 
(28), is overexpressed in VHL and SDHx-related PPGLs (29). VEGF activated in 
endothelial vascular cells within tumours can significantly contribute to 18F-FDG 
uptake (30).
 High SUVs observed in SDHx-related PPGLs could be related to the Warburg 
effect and thus we expected to find a stronger GLUT-1 and GLUT-3 expression in 
SDHx- compared to cluster 2-related PPGLs. However, we found no significant 
increase in immunohistochemical GLUT staining in SDHx-related tumours. We 
observed a predominantly cytoplasmic and weak membrane staining for both 
GLUT-1 and GLUT-3 as also reported by Blank et al (31). In addition, we found no 
correlation between GLUTs and SUVs in PPGLs. Taken together, these results 
suggest that glucose uptake may not be preferentially regulated by GLUT-1 and 
GLUT-3 in these tumours. Aloj et al. concluded that higher levels of glucose 
transporter protein do not guarantee increased FDG uptake by cancer cells (32). 
Differences in 18F-FDG uptake may be caused by differences in GLUT transporter 
activity rather than by differences in number of transporters present. Also, our 
findings suggest that the expression and recruitment of GLUTs to the cell 
membrane do not appear to vary in a genotype-specific way. 
 Instead of GLUT, higher 18F-FDG uptake in SDHx PPGLs might be related to 
expression of HKs. HK-2 showed an increased expression in SDHx-related PPGLs as 
predicted. The expression of HK-2 is regulated by HIF-1 and it is predominantly 
overexpressed in various cancer cells that display the Warburg effect (18) and 
associated with 18F-FDG uptake (20, 33). Favier et al. (10) also observed a significantly 
higher HK-2 gene expression in SDHx-related PPGLs compared to NF1 and RET 
related PPGLs. Immunohistochemical staining of HK-3 showed increased 
expression in SDHx-related PPGLs compared to sporadic tumours but when 
compared with cluster 2 tumours no significant increased expression was found. 
In addition, we found a stronger correlation between HK-3 and SUV than HK-2. A 
study using rat hepatoma cell line N1S1 reported the role of hypoxia signaling in 
the regulation of HK-3 (22). However, little is known about its regulation by HIFs 
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in PPGLs. Thus, increased glucose phosphorylation by HKs rather than the glucose 
transport by GLUTs is reflected as increased 18F-FDG uptake. Also, we assessed 
expression of HK-1 and observed lack of differences among different genotypes as 
it is a housekeeping enzyme ubiquitously expressed in mammalian tissues 
independent of HIF and is unaltered in most cancer cells (34).
 Increase in HK-2 and HK-3 expression in SDHx-related PPGLs point towards 
increased glycolysis, which we further investigated by assessing expression of 
MCT-4. This monocarboxylate transporter exports lactate out of the cell and its 
expression is known to be high in cells with increased glycolysis and lactate 
production. We found membrane as well as cytoplasmic staining for MCT-4 but 
the levels of expression did not vary among the different genotypes. However, 
Favier et al. (10) reported an increased expression of MCT-4 at the mRNA level 
in SDHx-related tumours. Thus, though evidence suggests increased glycolysis 
in SDHx-related tumours, it might not be accompanied by increased lactate 
production.
 We determined expression of VEGF to further explore our hypothesis that 
higher 18F-FDG uptake in SDHx-related PPGLs is reflective of the Warburg effect. 
A significantly increased expression of VEGF was observed, suggesting an increase 
in microvessel density in SDHx-related PPGLs. These results are in line with our 
previous estimations of mRNA levels measured by qPCR (35) and with Blank et al. 
(31) who also observed a significant correlation between SDHB-related PPGLs and 
microvessel density. VEGF stimulates angiogenesis but this probably will not 
necessarily result in higher uptake of 18F-FDG since newly formed vessels can be 
leaky and do not provide tumour cells with nutrients like glucose. Therefore, we 
also investigated CD34, marker for more mature endothelial cells. An increase in 
percentage of anti-CD34 staining was confirmed by quantitative analysis of CD34 
immunohistochemical staining. Moreover, mean vascular perimeter was 
significantly higher in SDHx-related tumours compared to cluster 2 and sporadic 
tumours. Nevertheless, no statistical differences in microvessel density were 
observed which could be attributed to highly heterogenous vascular patterns 
observed in these tumours. Taken together, increased endothelial surface area in 
this type of tumours can potentially contribute to higher accumulation of 18F-FDG, 
supporting the idea that functionality of vessels is more critical for SUVs than 
microvessel density.
 Additional studies with a larger sample size are needed to further explore the 
genotype-specific signature of expression of markers of the Warburg effect and 
their impact on functional imaging of these tumours. Also, somatic mutations in 
apparently sporadic tumours will need to be taken into account. Besides genetic 
factors, the influence of the microenvironment on the metabolism of tumour cells 
deserves further investigations. Furthermore, besides immunohistochemistry, 
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a more quantitative approach such as western blotting (not performed in the 
present study due to limited sample quantity) would be useful for better 
assessment of the expression of the investigated markers. In addition, SUVs 
merely provide a semi-quantitative measurement of 18F-FDG uptake, not providing 
information on the actual exchange of 18F-FDG between the intra- and extracellular 
compartment. This would require a dynamic scanning approach. In addition, 
considering the heterogeneous uptake pattern observed in some tumours, both 
SUVmean and SUVmax have their limitations regarding their representativeness for 
the tumour as a whole and the correlation with tissue markers. 
5.5  Conclusion
Activation of aerobic glycolysis in SDHx-related PPGLs is associated with increased 
18F-FDG accumulation due to accelerated glucose phosphorylation by hexokinases 
rather than increased expression of glucose transporters. Differences in tumour 
vasculature and the activity of transporter systems may also contribute to 
 genotype-related SUVs.
100
5.6  References
1. Gimenez-Roqueplo AP, Dahia PL, Robledo M. An update on the genetics of paraganglioma, pheochro-
mocytoma, and associated hereditary syndromes. Horm Metab Res. 2012;44(5):328-333.
2. Eisenhofer G, Huynh TT, Pacak K, Brouwers FM, Walther MM, Linehan WM, Munson PJ, Mannelli M, 
Goldstein DS, Elkahloun AG. Distinct gene expression profiles in norepinephrine- and epineph-
rine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven 
angiogenic pathways in von Hippel-Lindau syndrome. Endocr Relat Cancer. 2004;11(4):897-911.
3. Lopez-Jimenez E, Gomez-Lopez G, Leandro-Garcia LJ, Munoz I, Schiavi F, Montero-Conde C, de Cubas 
AA, Ramires R, Landa I, Leskela S, Maliszewska A, Inglada-Perez L, de la Vega L, Rodriguez-Antona C, 
Leton R, Bernal C, de Campos JM, Diez-Tascon C, Fraga MF, Boullosa C, Pisano DG, Opocher G, Robledo 
M, Cascon A. Research resource: Transcriptional profiling reveals different pseudohypoxic signatures 
in SDHB and VHL-related pheochromocytomas. Mol Endocrinol. 2010;24(12):2382-2391.
4. Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Havekes B, Eisenhofer G, Martiniova L, 
Adams KT, Pacak K. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopa-
mine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. 
The Journal of clinical endocrinology and metabolism. 2009;94(12):4757-4767.
5. Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Eisenhofer G, King KS, Rao JU, Wesley RA, 
Adams KT, Pacak K. Staging and functional characterization of pheochromocytoma and 
paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. Journal of the 
National Cancer Institute. 2012;104(9):700-708.
6. Timmers HJ, Kozupa A, Chen CC, Carrasquillo JA, Ling A, Eisenhofer G, Adams KT, Solis D, Lenders JW, 
Pacak K. Superiority of fluorodeoxyglucose positron emission tomography to other functional 
imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and 
paraganglioma. Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology. 2007;25(16):2262-2269.
7. Taieb D, Sebag F, Barlier A, Tessonnier L, Palazzo FF, Morange I, Niccoli-Sire P, Fakhry N, De Micco C, 
Cammilleri S, Enjalbert A, Henry JF, Mundler O. 18F-FDG avidity of pheochromocytomas and 
paragangliomas: a new molecular imaging signature? Journal of nuclear medicine : official 
publication, Society of Nuclear Medicine. 2009;50(5):711-717.
8. Blanchet EM, Gabriel S, Martucci V, Fakhry N, Chen CC, Deveze A, Millo C, Barlier A, Pertuit M, 
Loundou A, Pacak K, Taieb D. F-FDG PET/CT as a predictor of hereditary head and neck paragangliomas. 
European journal of clinical investigation. 2014.
9. Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Kerlan V, Plouin PF, Rotig A, Jeunemaitre X. 
Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. 
The Journal of clinical endocrinology and metabolism. 2002;87(10):4771-4774.
10. Favier J, Briere JJ, Burnichon N, Riviere J, Vescovo L, Benit P, Giscos-Douriez I, De Reynies A, Bertherat 
J, Badoual C, Tissier F, Amar L, Libe R, Plouin PF, Jeunemaitre X, Rustin P, Gimenez-Roqueplo AP. The 
Warburg effect is genetically determined in inherited pheochromocytomas. PLoS One. 
2009;4(9):e7094.
11. Rao JU, Engelke UF, Rodenburg RJ, Wevers RA, Pacak K, Eisenhofer G, Qin N, Kusters B, Goudswaard 
AG, Lenders JW, Hermus AR, Mensenkamp AR, Kunst HP, Sweep FC, Timmers HJ. Genotype-specific 
abnormalities in mitochondrial function associate with distinct profiles of energy metabolism and 
catecholamine content in pheochromocytoma and paraganglioma. Clinical cancer research : an 
official journal of the American Association for Cancer Research. 2013;19(14):3787-3795.
12. Jochmanova I, Yang C, Zhuang Z, Pacak K. Hypoxia-inducible factor signaling in pheochromocyto-
ma: turning the rudder in the right direction. J Natl Cancer Inst. 2013;105(17):1270-1283.
13. Gordan JD, Simon MC. Hypoxia-inducible factors: central regulators of the tumour phenotype. 
Current opinion in genetics & development. 2007;17(1):71-77.
14. Dahia PL, Familial Pheochromocytoma C. Transcription association of VHL and SDH mutations link 
hypoxia and oxidoreductase signals in pheochromocytomas. Annals of the New York Academy of 
Sciences. 2006;1073:208-220.
101
18F-FDG PET in PPGL
5
15. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, 
Thompson CB, Gottlieb E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting 
HIF-alpha prolyl hydroxylase. Cancer cell. 2005;7(1):77-85.
16. Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309-314.
17. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) 
proteins in cancer. Journal of cellular physiology. 2005;202(3):654-662.
18. Mathupala SP, Ko YH, Pedersen PL. Hexokinase-2 bound to mitochondria: cancer’s stygian link to the 
“Warburg Effect” and a pivotal target for effective therapy. Seminars in cancer biology. 2009;19(1):17-24.
19. Ahn KJ, Hwang HS, Park JH, Bang SH, Kang WJ, Yun M, Lee JD. Evaluation of the role of hexokinase 
type II in cellular proliferation and apoptosis using human hepatocellular carcinoma cell lines. 
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2009;50(9):1525-1532.
20. Yamada T, Uchida M, Kwang-Lee K, Kitamura N, Yoshimura T, Sasabe E, Yamamoto T. Correlation of 
metabolism/hypoxia markers and fluorodeoxyglucose uptake in oral squamous cell carcinomas. 
Oral surgery, oral medicine, oral pathology and oral radiology. 2012;113(4):464-471.
21. de Geus-Oei LF, van Krieken JH, Aliredjo RP, Krabbe PF, Frielink C, Verhagen AF, Boerman OC, Oyen 
WJ. Biological correlates of FDG uptake in non-small cell lung cancer. Lung cancer. 2007;55(1):79-87.
22. Wyatt E, Wu R, Rabeh W, Park HW, Ghanefar M, Ardehali H. Regulation and cytoprotective role of 
hexokinase III. PloS one. 2010;5(11):e13823.
23. Dierckx RA, Van de Wiele C. FDG uptake, a surrogate of tumour hypoxia? European journal of nuclear 
medicine and molecular imaging. 2008;35(8):1544-1549.
24. Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by 
hypoxia. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 1995;36(9):1625-1632.
25. Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, Oyen WJ, Kotzerke 
J, Hoekstra OS, Pruim J, Marsden PK, Tatsch K, Hoekstra CJ, Visser EP, Arends B, Verzijlbergen FJ, 
Zijlstra JM, Comans EF, Lammertsma AA, Paans AM, Willemsen AT, Beyer T, Bockisch A, Schae-
fer-Prokop C, Delbeke D, Baum RP, Chiti A, Krause BJ. FDG PET and PET/CT: EANM procedure guidelines 
for tumour PET imaging: version 1.0. European journal of nuclear medicine and molecular imaging. 
2010;37(1):181-200.
26. Eisenhofer G, Pacak K, Huynh TT, Qin N, Bratslavsky G, Linehan WM, Mannelli M, Friberg P, Grebe SK, 
Timmers HJ, Bornstein SR, Lenders JW. Catecholamine metabolomic and secretory phenotypes in 
phaeochromocytoma. Endocrine-related cancer. 2011;18(1):97-111.
27. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic 
requirements of cell proliferation. Science. 2009;324(5930):1029-1033.
28. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148(3):399-408.
29. Favier J BJ, Burnichon N, Rivière J, Vescovo L, Benit P, Giscos-Douriez I, De Reyniès A, Bertherat J, 
Badoual C, Tissier F, Amar L, Libé R, Plouin PF, Jeunemaitre X, Rustin P, Gimenez-Roqueplo AP. The 
Warburg effect is genetically determined in inherited pheochromocytomas. PLoS One. 2009;18(4(9)).
30. Maschauer S PO, Hoffmann M, Deichen JT, Kuwert T. Characterization of 18F-FDG uptake in human 
endothelial cells in vitro. J Nucl Med. 2004;45(3):455-460.
31. Blank A, Schmitt AM, Korpershoek E, van Nederveen F, Rudolph T, Weber N, Strebel RT, de Krijger R, 
Komminoth P, Perren A. SDHB loss predicts malignancy in pheochromocytomas/sympathethic 
paragangliomas, but not through hypoxia signalling. Endocrine-related cancer. 2010;17(4):919-928.
32. Aloj L, Caraco C, Jagoda E, Eckelman WC, Neumann RD. Glut-1 and hexokinase expression: relationship 
with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Res. 1999;59(18):4709-
4714.
33. Watanabe Y, Suefuji H, Hirose Y, Kaida H, Suzuki G, Uozumi J, Ogo E, Miura M, Takasu K, Miyazaki K, 
Nakahara K, Ishibashi M, Okamura T, Ohshima K, Hayabuchi N. 18F-FDG uptake in primary gastric 
malignant lymphoma correlates with glucose transporter 1 expression and histologic malignant 
potential. International journal of hematology. 2013;97(1):43-49.
34. Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, Cairns R, Hawkins C, Guha A. Hexokinase 2 is a 
key mediator of aerobic glycolysis and promotes tumour growth in human glioblastoma multiforme. 
The Journal of experimental medicine. 2011;208(2):313-326.
102
35. Span PN, Rao JU, Oude Ophuis SB, Lenders JW, Sweep FC, Wesseling P, Kusters B, van Nederveen FH, 
de Krijger RR, Hermus AR, Timmers HJ. Overexpression of the natural antisense hypoxia-inducible 
factor-1alpha transcript is associated with malignant pheochromocytoma/paraganglioma.  Endocrine- 
related cancer. 2011;18(3):323-331.
36. Vlems F, van der Worp E, van der Laak J, van de Velde C, Nagtegaal I, van Krieken H. A study into 
methodology and application of quantification of tumour vasculature in rectal cancer. Virchows 
Archiv : an international journal of pathology. 2004;445(3):263-270.
103
18F-FDG PET in PPGL
5
5.7  Supplementary Methods
Quantitative PCR
Total RNA was isolated using the Total RNA purification Kit (Norgen Biotek Corp) 
with on-column DNase-I treatment. RNA concentrations were determined by 
measuring the spectrophotometric absorption at 260 nm using the GeneQuant 
(Amersham). cDNA synthesis was performed using 500 ng total RNA and 8 µl 5X 
iScript reaction mix (Bio-Rad) containing oligo dT primers, with a total volume of 
40 µl. cDNA synthesis was performed using a heating block. Samples were 
denatured for 10 min at 700C and cDNA synthesis was performed for 60 min at 
420C, followed by an enzyme inactivation step for 5 min at 990C. Quantitative PCR 
(qPCR) was performed to determine the expression levels of HK-2, GLUT-3 and β2 
Microglobulin (β2M) mRNAs in 22 PPGL tumour tissues. The primers used for the 
reactions are as follows: HK-2 Forward Primer 5’ TCAGATTGAGAGTGACTGCC 3’ 
and Reverse Primer 5’ TTTCTCGTATCCTGTCCACC 3’ GLUT-3 Forward Primer 5’GTG-
GCCCAGATCTTTGGTC3’ and Reverse Primer 5’ AAGGGCTGCACTTTGTAGG3’ β2M 
Forward Primer 5’ATGAGTATGCCTGCCGTGTG3’ Reverse Primer 5’CCAAATGCGG-
CATCTTCAAAC3’. Reactions were performed using SYBR green PCR master mix 
(Applied Biosystems). cDNA equivalent of 10 ng total RNA was used for each 
reaction and the reactions were performed in a total volume of 10 µl in ABI Prism 
7500 sequence detector (Applied Biosystems). The amplification reactions were 
carried out with denaturation at 95 0C for 10 min, 40 cycles of 15 s at 950C (melting), 
and 60 s at 600C (annealing and elongation). The expression of the mRNAs was 
calculated relative to the levels of the internal control gene β2M. The relative 
expression levels were determined by the 2-ΔCt method.
Immunohistochemical staining and quantification
Tumour tissue sections were deparaffinized, rehydrated and washed with 50 mM 
phosphate buffered saline (PBS). Antigen retrieval was performed by boiling the 
sections in 10 mM citrate, pH 6.0 in a microwave for 3 minutes at 850W followed 
by 10 minutes at 150 W. Endogenous peroxidase activity was blocked with 3% 
hydrogen peroxide (H2O2) in PBS for 30 minutes. For HK-1, 2 and 3 staining, 
endogenous peroxidase activity was blocked by incubation with 0.6% H2O2 in 
40% methanol and 60% 50 mM PBS for 30 minutes. Subsequently, the sections 
were washed with PBS. Non-specific interactions were blocked using normal 
human serum (5% in PBS for 30 minutes) for HK-1, 2 and 3, normal goat serum 
(20% in PBS) for VEGF, MCT-4, (30 minutes) GLUT-1 and -3 (10 minutes) respectively. 
For GLUT-1 prior to incubation with the primary antibody, avidin and biotin block 
(Vector Laboratories, SP-2001) was performed for 15 minutes each. Primary 
antibody diluted in 0.1% BSA/PBS was applied (supplementary Table 2) for 60 
104
minutes for HK-1, HK-2, HK-3, CD34 and GLUT-3, 90 minutes for MCT-4 and 
overnight for GLUT-1 and VEGF at 4 °C. The sections were then washed with 50 mM 
PBS, followed by incubation with the secondary antibody for 30 minutes 
(supplementary Table 2). Slides stained for HK-1, HK-2, HK-3 and GLUT-1 were incubated 
with avidin biotin reagent (Vectastain Elite ABC Kit, Vector Laboratories, PK6100) for 
45 minutes. The sections were washed with PBS and incubated with 3,3-diamino-
benzidine (DAB) (Immunologic, BS04-110) for 10 minutes. After washing DAB with 
running tap water for 5 minutes, the sections were counterstained with hematoxylin 
for 10 seconds, washed and dehydrated in ethanol series (50%, 70%, 100%) followed 
by xylene and mounted with permount.
 Expression of various markers was quantified by evaluating the amount of 
DAB staining by an experienced pathologist (BK) who was unaware of the 
patient’s clinical data while CD34 was scored automatically. The percentage of the 
positive stained area of the sections was graded in a scale ranging from 0-100%. 
The intensity of the DAB color was graded as non-staining (0), faint staining (I), 
medium staining (II) and intense staining (III), ignoring the background color of 
the staining. Areas containing adrenal cortex, brown fat and capillaries were 
used as controls for comparison between different sections. The intensity of each 
marker was evaluated separately. Cytoplasmic staining was evaluated for HK-1, 
HK-2, HK-3 and VEGF. For GLUT-1, GLUT-3 and MCT-4 cytoplasmic and/or membrane 
staining was graded as they were expressed both in the cytoplasm and membrane. 
The score of the staining represents the expression of the markers and is based on the 
multiplication of the intensity with the percentage of the positive stained area.
 For CD34 scoring, image acquisition was performed using a CCD color camera 
(AxioCam MRc; Carl Zeiss AG, Jena, Germany) mounted on a conventional light 
microscope (AxioPhot; Carl Zeiss AG, Jena, Germany) and attached to a personal 
computer. Images were acquired using a x20 objective (Plan Neofluar, NA = 0.5, 
resulting in specimen level pixel size of 0.53x0.53 µm2). Prior to analysis of the 
 immunohistochemical staining, an image of an empty microscopic field was 
acquired, which was used for correction for unequal illumination. Image 
acquisition and analysis were performed using a custom written macro in KS400 
image analysis software (Carl Zeiss), as described previously (36). Thresholds for 
recognition of CD34-positivity were determined from a set of training slides and 
were found adequate for almost all slides analyzed in this study. When the initial 
thresholds led to unrealistic patterns, interactive adjustment was performed by 
the operator. For each patient, the percentage of anti-CD34 stained area, the 
microvessel density and the vessel perimeter were calculated per surface area 
tumour in ten randomly selected images.
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Supplementary Table 2  Details of antibodies used for immunohistochemistry
Primary 
antibody
Host Concentration 
(µg/ml)
Manufacturer 
/ Catalog 
number
Secondary 
antibody
Concentration 
(µg/ml)
Manufacturer 
/ Catalog 
number
HK-1 Goat 10 Santa Cruz 
Biotechnology 
SC 6518
Rabbit anti 
goat biotin
4 DAKO, EO466
HK-2 Goat 3 Santa Cruz 
Biotechnology 
SC 6521
HK-3 Goat 10 Santa Cruz 
Biotechnology 
SC 6523
GLUT-1 Rabbit 1 Thermo 
Scientific  RB-
9052-PO
Goat anti 
rabbit 
biotin
7.5 Vector 
Laboratories, 
BA-1000
GLUT-3 Mouse Neat Thermo 
Scientific PA1-
28204
Goat 
polyclonal 
anti- 
mouse/
rat/ rabbit 
peroxidase
1:1 of neat Immunologic, 
DPVO 110HRP
MCT-4 Rabbit 5 Millipore 
AB3316P
VEGF Rabbit 32 Gifted by  dept. 
of Laboratory 
Medicine, 
RUNMC
CD-34 Mouse 1:200 Immunologic 
ILM 1343
Immunologic, 
DVPO 999HRP
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Supplementary Figure 1  Expression of (A) Hexokinase 2 and (B) glucose transporter type 
3 mRNA in PGL tumours. Expression of mRNAs in PPGL tumours were investigated using 
qPCR and their relative expression levels across different genotypes are plotted. Groups 
with different letters as superscripts are significantly different.
A
B
109
18F-FDG PET in PPGL
5

Discussion
6

113
Discussion
6
The focus of this doctoral thesis is to investigate the impact of genotype-specific 
differences in energy metabolism of PPGLs on catecholamine metabolism, 
imaging and metastatic potential. Initial work in this area focused on 
understanding differences in gene expression between cluster 1 and cluster 2 
PPGLs.  Cluster 1 tumours (VHL, SDHA/B/C/D/AF2) are characterized by increased 
expression of genes involved in (pseudo) hypoxia, cell proliferation, angiogenesis, 
electron transport chain and the Krebs cycle, and abnormal function of oxidore-
ductases (1). Cluster 2 tumours (RET, NF1) show an increased expression of genes 
involved in protein synthesis, kinase signaling, endocytosis, and maintenance of 
a differentiated chromaffin cell catecholamine biosynthetic and secretory 
phenotype. Subsequent studies focused on alterations in respiratory chain 
enzyme activities in SDHx tumours in comparison with tumours of other 
genotypes (2,3). Studies on catecholamine metabolism and secretory phenotype 
also investigated the causes for the observed genotype-specific differences in 
catecholamine biosynthetic and secretory profile (4,5). In parallel, studies also 
investigated the efficacy of 18F-FDG-PET imaging in localizing metastatic PPGLs 
especially those with an underlying SDHB mutation (6,7). How genotype-specific 
alterations in energy metabolism underlie these various pathophysiological 
aspects of PPGLs was investigated in a series of studies composing the present 
thesis.      
6.1   Relating energy metabolism to catecholamine, 
amino acid and purine metabolism in PPGLs
Towards this end, in the study that constitutes the first chapter of this thesis, we 
investigated genotype-specific differences in mitochondrial energy metabolism 
in PPGLs. The study provided novel insight into how deregulation of energy 
metabolism might impact catecholamine phenotypic features of cluster 1 and 
cluster 2 tumours. In accordance with previous reports (2,3,8,9), we observed that 
the activity of SDH (complex II) is low in SDH-related tumours. Interestingly, 
reduction of complex II activity in SDH-related tumours was associated with 
increased activities of respiratory chain complexes I, III, and IV and citrate 
synthase. The increased citrate synthase activity also indicated an increase in the 
mitochondrial content in SDH-related tumours. A similar increase in activities of 
complexes I and III and citrate synthase in SDH-related tumours when compared 
to VHL-related ones was also observed by Fliedner et al. (10). However, despite the 
apparent increase in activity of complexes I, III, and IV and citrate synthase in the 
tumours, ATP/ADP/AMP levels were low. Interestingly, in contrast to SDH-related 
tumours, we observed a trend of down regulation of all respiratory chain enzyme 
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activities in VHL tumours. Also, we observed that in contrast to VHL tumours, 
levels of ATP/ADP/AMP in SDHx tumours were undetectable.
 Genotype-specific differences in catecholamine production in PPGLs are well 
known. In line with previous reports by Eisenhofer and colleagues (4,11-13), in the 
present study we observed that tumours with mutations in VHL and SDHx mainly 
produce noradrenaline and those with mutations in RET and NF1 produce both 
adrenaline and noradrenaline. We also observed that the tumour tissue total 
catecholamine content was lower in SDHx tumours when compared to RET and 
sporadic PPGLs. This difference in the catecholamine phenotype has been 
attributed to the lack of the enzyme phenylethanolamine N-methyltransferase in 
VHL and SDHx tumours (14). Interestingly, we observed a positive relationship 
between complex II function, tumour ATP/ADP/AMP content and tumour 
catecholamine contents suggesting the possibility that differences in energy 
metabolism might also contribute to the lower tumour tissue catecholamine 
contents in cluster 1 than in cluster 2 tumours. This inference is supported by the 
fact that the sequestration of catecholamines into secretory vesicles and re-uptake 
of catecholamines into chromaffin cells are active energy dependent processes. 
Sequestration of catecholamines is facilitated by VMATs. The H+ gradient 
necessary to maintain the activity of VMATs is generated by the ATP-dependent 
vesicular membrane proton pump (15). Chromaffin granules also contain 
strikingly high concentrations of ATP due to the activity of vesicular nucleotide 
transporter (16). This contributes to the stability and enables chromaffin granules 
to maintain catecholamine stores (17,18). Furthermore, NET responsible for the 
sodium and chloride (Na+/Cl-) dependent reuptake of extracellular norepinephrine 
and dopamine is also indirectly dependent on cellular store of ATP. NET functions 
by coupling the transport of norepinephrine and dopamine with the influx of 
sodium and chloride (Na+/Cl-). The ion gradients of Na+ and Cl- generated by the 
Na+/K+-ATPase make this reuptake energetically favorable (17-19). Clearly 
therefore, energy metabolism has an important role in maintaining the stability 
of chromaffin granules and thus catecholamine storage. Thereby, it seems possible 
that genotype-specific differences in the energy metabolism, along with 
associated differences in expression of various genes encoding components of 
secretory pathway and exocytotic machinery (20), could in conjunction contribute 
to genotype-specific differences in tumour catecholamine phenotypic features.
 In in vitro experiments with cells silenced for SDH, it was observed that the 
accumulation of succinate leads to stabilization of HIF-1α (21). In the present study, 
for the first time we provide ex vivo evidence for accumulation of succinate in 
SDHx tumours. This was later confirmed in a large cohort of patients by Richter 
and colleagues (22). They further extended the study to detect various Krebs cycle 
intermediates in PPGLs and studied the use of succinate: fumarate ratio as a 
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diagnostic marker to detect SDHx mutations in PPGL patients. Recently, Favier and 
colleagues reported in vivo detection of succinate using in vivo NMR spectroscopy 
further confirming our initial report (23) (24).
 We further extended the results of genotype-specific differences in metabolite 
levels using multiple complementary analytical methods to further investigate 
genotype-specific differences in tumour metabolite profile. The results of this 
study presented in chapter 2 demonstrate that the differences in metabolite 
profiles can be used to differentiate the genotypes using unsupervised statistical 
methods. In this study, we used two different metabolite profiling platforms 
namely, NMR and LC-tandem-MS. We used NMR as an untargeted metabolite 
profiling technique allowing detection of the vast majority of proton containing 
compounds in the low micromolar or higher concentration range. For targeted 
metabolite profiling, we used LC-tandem MS to test the presence of genotype-spe-
cific differences in the concentration of various purines in the tumours. We used 
PCA as an unsupervised method for interpretation of NMR spectra and to classify 
the samples in genotype-specific groups on the basis of their metabolite profile. 
The peak positions contributing to maximum variability in the first three 
principal components included epinephrine, succinate, lactic acid and high 
energy phosphates of adenosine. The lactic acid levels however need to be 
interpreted with caution as the lactate levels in resected tumour samples are not 
always reflective of the actual metabolism.
 One of the striking observations of NMR spectra of SDH-related tumours was 
the lack of peaks of high energy phosphates of adenosine which suggested that 
there could be a total lack of adenine content in SDHx tumours. This hypothesis 
was verified by assessing the content of purines in PPGLs using LC-tandem MS. As 
described in chapter 2, we observed that the levels of adenine and adenosine were 
lower in SDHx tumours when compared to RET-related tumours. Inosine levels 
were lower in cluster 1 tumours compared to cluster 2 tumours in contrast to 
hypoxanthine levels which were lower in cluster 2 tumours when compared to 
cluster 1 tumours. We hypothesize that in the de novo synthesis of the purine 
nucleotides, possibly the activity of inosine monophosphate (IMP) dehydrogenase 
is higher in SDH tumours while in the RET-related ones, adenylosuccinate synthase 
and/or lyase activities are higher. Thus, the IMP that is formed by the de novo 
pathway is committed to either of the purine biosynthetic branches in a geno-
type-specific way (Figure 3, Chapter 2).
 In this study, for the first time we report the presence of N-Acetyl aspartic acid 
(NAA) in the peripheral nervous system. NAA is synthesized in mitochondria 
through acetylation of aspartate by L-Asparatate N-acetyl transferase, a 
membrane bound enzyme, in the neuronal tissue (25). Mitochondrial NAA 
production is dependent on functioning of respiratory chain enzyme complexes 
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and oxidative phosphorylation. Inhibition of these enzymes leads to significant 
decrease in mitochondrial NAA and ATP production in isolated rat brain 
mitochondria (26). This relates well with our observation of strong positive 
correlation between NAA content and respiratory chain complex II activity and 
NAA and ATP/ADP/AMP contents in PPGLs. Similar to patients with mitochondrial 
encephalomyelopathies, we observed low NAA/total creatine ratio in tumours 
with compromised mitochondrial function. Thus, the NAA levels in SDH and VHL 
tumours are directly linked to the energetic states of the tumour cell mitochondria.
 The metabolic features that characterize the SDHx and VHL tumours include 
lack of epinephrine, NAA and ATP/ADP/AMP while low levels of creatine and 
presence of lactate are more specific to VHL tumours. RET and NF-1 tumours on the 
other hand are distinguished by high levels of epinephrine, NAA, ATP/ADP/AMP, 
and creatine.
6.2  Hypoxia and metastatic potential
Stabilization of HIF-1α and 2α in cluster 1 PPGLs is caused by decreased 
pVHL-dependent proteasomal degradation by the E3 ubiquitin ligase complex or 
inhibition of prolyl hydroxylase activity due to succinate accumulation caused by 
mutations in the SDH subunit. This leads to increased transcription of 
HIF-dependent genes involved in tumourigenesis and angiogenesis (21). On the 
other hand, sustained increase in HIF-1α leads to decrease in HIF-1α mRNA. In vitro 
experiments in renal cell carcinoma cells have yielded an insight into oxygen 
dependent regulation of HIF-1α mRNA levels (27,28). As discussed in chapter 3, 
similar to these findings we observed that increased aHIF expression in parallel 
with VEGF in SDH- and VHL-related PGL fits a pattern of a chronic (pseudo)hypoxic 
state. This suggests that aHIF can serve as a surrogate marker of chronic HIF-1α 
activation, taking into account that measurement of the HIF-1α protein itself is 
cumbersome. Besides its involvement in expression of genes which lead to 
tumourigenesis, HIF-1α is also involved in stabilization of p53. aHIF expression 
leads to reduced levels of HIF-1α thus reducing the amount of p53 which is a 
contributing factor leading to aggressive tumour phenotype which has been 
demonstrated in other cancer types. As described in chapter 3, in PPGLs as well, 
aHIF expression in primary tumours turned out to be a predictor of decreased me-
tastasis-free survival. There are currently no reliable histological criteria for 
malignant PGL besides the presence of metastatic lesions in locations where 
chromaffin tissue is normally absent (29). The 5-year survival of patients with 
metastatic PGL is nearly 50% (30,31), and no cure is available. It is therefore critical 
to identify biomarkers of malignancy such as aHIF. Besides aHIF, VEGF was also 
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negatively correlated with metastasis-free survival which highlights the 
importance of anti-angiogenic therapy in PPGLs.
6.3   Role of hypoxia and altered energy metabolism  
in 18F-FDG uptake
Activation of the hypoxic-angiogenic pathway through stabilization of HIF-1α 
and -2α, leads to increased expression of genes involved in glucose metabolism 
(glucose transporters and hexokinases), angiogenesis, cell survival and cell 
motility (1,21). High uptake of 18F-FDG by SDHx-related tumours has been suggested 
to be a reflection of the Warburg effect. Thus, we examined the ex vivo expression 
of markers of the Warburg effect in PPGLs using immunohistochemical staining 
and their correlation with uptake of in vivo 18F-FDG on PET/CT scans. As reported 
in chapter 4, we observed an increased expression of Hexokinase 2 in SDHx-related 
tumours when compared to sporadic and cluster 2 tumours. 18F-FDG uptake of any 
tumour is dependent on amount of 18F-FDG that enters the cell through facilitative 
glucose transport via GLUTs as well as its phosphorylation through hexokinase 
which prevents escape of 18F-FDG from the tumour cell. Tumoural blood flow 
which brings in the nutrients and oxygen also plays a critical role in uptake of 
18F-FDG. However, in pseudohypoxia, activation of the hypoxic angiogenic 
pathway through stabilization of HIF-1α and -2α leads to uncoupling of the blood 
flow and metabolism implying hypoxic stimulation of glucose metabolism in the 
presence of adequate oxygen supply. We observed no increase in the expression of 
GLUT-1 or -3 transporters in cluster 1 tumours. However, an increased expression 
of hexokinase 2 and 3 and VEGF which correlated with the 18F-FDG uptake values 
was observed. Also, higher mean vascular perimeter in SDH-related tumours as 
determined by CD-34 staining could contribute to increased 18F-FDG uptake 
supporting the idea that permeability and functionality of the vessels is more 
critical for the uptake than microvessel density.
6.4  Conclusion
This thesis aimed at improving the understanding of the impact of genotype-spe-
cific differences in energy metabolism of PPGLs on catecholamine metabolism, 
imaging and metastatic potential. The studies presented in chapter 1 and 2 
concluded that based on differences in metabolite profiles, the PPGLs can be 
classified into different genotypes in an unsupervised fashion. Alterations in 
energy metabolism in SDH- and VHL-related tumours can have far reaching 
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impact on catecholamine content and secretion, purine metabolism and amino 
acid metabolism. Activation of hypoxic angiogenic pathway which leads to 
subversion of energy metabolism can also be used to predict metastatic potential. 
As discussed in chapter 3, aHIF and VEGF expressed as a result of activation of 
hypoxic-angiogenic pathway can be used as markers of metastatic potential. 
Subversion of energy metabolism by activation of hypoxic-angiogenic pathway is 
reflected in increased 18F-FDG uptake and increased 18F-FDG uptake is a result of 
increased expression of hexokinase 2 and 3 and probably increased vascular 
permeability and higher mean vascular perimeter. 
6.5  Future Perspectives
Study of energy metabolism is a relatively new area of research in the study of 
pathophysiology of PPGL. The studies described in the present thesis as well as 
recent reports by others have opened new possibilities in understanding patho-
physiology of SDH- and VHL-related PPGLs. A detailed study of alterations in 
energy metabolism using in vitro and in vivo metabolite labeling approaches will 
help in improved understanding of the pathophysiology. Genotype-specific 
differences in metabolism can be also used to direct alternative diagnostic and 
therapeutic options. Detection of succinate using in vivo NMR spectroscopy can 
be used for localization of SDHx related tumours. Also, detection of succinate, NAA 
and purines in tumour tissue using 1H NMR spectroscopy or LC-MS can help in 
inexpensive classification of PPGLs into different genotypes. Inhibitors of 
glycolysis which target hexokinases like 2-deoxy glucose, and 3-bromo pyruvate 
can be of interest especially using targeted drug delivery in SDH-related tumours 
as they show an increased expression of hexokinase and glycolytic activity as 
measured by increased 18F-FDG avidity (32,33). Shunting of inosine monophosphate 
to guanosine monophosphate synthesis could also be an attractive therapeutic 
target as it appears to be the active purine biosynthetic route in SDH-related 
tumours. Thus, studies on metabolism of PPGLs have opened up new diagnostic 
and therapeutic options especially in combination with targeted drug delivery. 
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Chapter 1 provides an overview of various aspects of pheochromocytomas and 
paragangliomas (PPGLs). Pathophysiology and alterations in metabolism in relation 
to genetic background as well as impact of the above on functional imaging of 
PPGL are discussed in order to introduce the studies that the thesis comprises. 
The aim of this thesis was to study the impact of genotype-specific alterations in 
tumour energy metabolism in PPGLs on diagnostic characteristics and metastatic 
potential. For this purpose, targeted and untargeted ex-vivo metabolomic investigations 
of PPGL tumour tissues were compared with clinical characteristics and in vivo 
functional imaging of patients. 
 In Chapter 2, a study that investigates the relationships between genotype- 
specific differences in mitochondrial function and catecholamine content in 
PPGLs is described. Respiratory chain enzyme assays and untargeted metabolite 
profiling with 1H NMR spectroscopy at 500 MHz were conducted on homogenates 
of 35 sporadic PPGLs and 59 PPGLs from patients with hereditary mutations in 
SDHB, SDHD, SDHAF-2, VHL, RET, NF1, and MAX. In SDH-related PPGLs, a significant 
decrease in complex II activity and a significant increase in complex I, III, and IV 
enzyme activities were observed when compared to sporadic, RET, and NF1 tumours. 
Also, a significant increase in citrate synthase enzyme activity (P < 0.0001) was 
observed in SDH-related PPGLs when compared to sporadic-, VHL-, RET-, and 
NF1-related tumours. A significant increase in succinate accumulation and a 
significant decrease in ATP/ADP/AMP levels were observed when compared to 
sporadic PPGLs and PPGLs of other genotypes. Positive correlations were observed 
between respiratory chain complex II activity and total catecholamine content 
and ATP/ADP/AMP and total catecholamine contents in tumour tissues. This 
study for the first time establishes a relationship between determinants of energy 
metabolism (activity of respiratory chain enzyme complex II, ATP/ADP/AMP 
content) and catecholamine content in PPGL tumours. Also, this study for the first 
time successfully uses NMR spectroscopy to detect catecholamines in PGL tumours 
and provides ex-vivo evidence for the accumulation of succinate in PPGLs with an 
SDHx mutation.
 Chapter 3 is an extension of the previous chapter which investigates in detail 
the effect of genetic alterations on metabolic networks in PPGLs. In this study, 
homogenates of 32 sporadic PPGLs and 48 PPGLs from patients with mutations 
in SDHB, SDHD, SDHAF-2, VHL, RET, and NF-1 were subjected to proton 1H NMR 
spectroscopy at 500 MHz for untargeted and LC tandem mass spectrometry for 
targeted metabolite profiling. 1H NMR spectroscopy identified 28 metabolites in 
PPGLs of which 12 showed genotype-specific differences. Extending the results 
described in chapter 2, significantly low levels of NAA in SDHx tumours and 
creatine in VHL tumours were observed compared with sporadics and other 
genotypes. Positive correlation was observed between NAA and ATP/ADP/AMP 
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content and NAA and complex II activity of PGLs. Targeted purine analysis in 
PPGLs showed significantly low adenine levels in cluster 1 compared to cluster 2 
tumours whereas significantly low levels of guanosine and hypoxanthine were 
observed in RET tumours compared with SDH tumours. Principal component 
analysis (PCA) of metabolites could distinguish PPGLs of different genotypes. This 
study gives a comprehensive picture of alterations in energy metabolism in SDH- 
and VHL-related PPGLs and establishes the interrelationship of energy metabolism 
and amino acid and purine metabolism in PPGLs.
 The study described in chapter 4 tests the hypothesis that genotype-specific 
overexpression of antisense HIF (aHIF) is associated with an increased metastatic 
potential. Tumour samples were collected from 87 patients with PPGL. Quantitative 
PCR was performed for aHIF, vascular endothelial growth factor (VEGF), aquaporin 3, 
cytochrome b561, p57Kip2, slit homolog 3, and SDHC. Expression was related to 
mutation status, benign versus malignant tumours, and metastasis-free survival. 
We found that both aHIF and VEGF were overexpressed in cluster 1 PPGLs and in 
metastatic tumours. In contrast, slit homolog 3, p57Kip2, cytochrome b561, and 
SDHC showed overexpression in non-metastatic tumours, whereas no such 
difference was observed for aquaporin 3. Patients with higher expression levels of 
aHIF and VEGF had a significantly decreased metastasis-free survival. Higher 
expression levels of SDHC are correlated with an increased metastasis-free 
survival. In conclusion, we not only demonstrate a higher expression of VEGF in 
cluster 1 PPGL, fitting a profile of pseudohypoxia and angiogenesis, but also of 
aHIF. Moreover, overexpression of aHIF and VEGF marks a higher metastatic 
potential in PPGL.
 The study described in chapter 5, tests the hypothesis that increased uptake 
of 18F-FDG in SDH-related PPGLs is reflective of increased glycolytic activity and 
is correlated with expression of different proteins involved in glucose uptake and 
metabolism through the glycolytic pathway. Twenty-seven PPGLs collected from 
patients with hereditary mutations in SDHB (n = 2), SDHD (n = 3), RET (n = 5), neuro-
fibromatosis 1 (n = 1) and MAX (n = 1) and sporadic patients (n = 15) were investigated. 
Preoperative 18F-FDG PET/CT studies were analyzed, mean and maximum 
standardized uptake values (SUVs) in manually drawn regions of interest were 
calculated. The expression of proteins involved in glucose uptake (GLUT-1 and -3, 
respectively), phosphorylation (HK-1, -2, and -3, respectively), glycolysis (MCT-4), 
and angiogenesis (VEGF, CD34) were examined in paraffin-embedded tumour 
tissues using immunohistochemical staining with peroxidase-catalyzed 
polymerization of diaminobenzidine as a read-out. The expression was correlated 
with corresponding SUVs. Both maximum and mean SUVs for SDH-related 
tumours were significantly higher than those for sporadic and other hereditary 
tumours. The expression of HK-2 and HK-3 was significantly higher in SDH-related 
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PPGLs than in sporadic PPGLs (P = 0.022 and 0.025, respectively). The expression of 
HK-2 and VEGF was significantly higher in SDH-related PPGLs than in other 
hereditary PPGLs (P = 0.039 and 0.008, respectively). No statistical differences in 
the expression were observed for GLUT-1, GLUT-3, and MCT-4. The percentage 
anti-CD 34 staining and mean vessel perimeters were significantly higher in 
SDH-related PPGLs than in sporadic tumours. Mean SUVs correlated with the 
expression of HK-2, HK-3, VEGF, and MCT-4. The activation of aerobic glycolysis in 
SDH-related PPGLs is associated with increased 18F-FDG accumulation due to 
accelerated glucose phosphorylation by hexokinases rather than increased expression 
of glucose transporters.
 Chapter 6 presents a general discussion of the results and observations 
presented through the thesis. In addition, future perspectives on the utilization of 
the results of the studies presented in the thesis to improve the diagnostic and 
therapeutic options available for PPGLs are discussed.
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Hoofdstuk 1 betreft een overzicht van diverse aspecten van feochromocytoom en 
paraganglioom (PPGL). De pathofysiologie en de kenmerken van het tumourcel-
metabolisme bij specifieke genetische mutaties worden besproken. Dit in relatie 
tot de klinische fenotypen en kenmerken bij diagnostisch onderzoek. Het doel van 
dit promotieonderzoek was het bepalen van de effecten van genotype-specifieke 
veranderingen in tumour metabolisme op de diagnostische karakteristieken van 
PPGL en op maligne kenmerken. Voor dit doel werden de metabole profielen van 
ex-vivo PPGL tumourweefsels onderzocht en vergeleken met klinische karakteris-
tieken van patiënten en met in vivo functional imaging resulaten.
In hoofdstuk 2 wordt een studie beschreven naar de relatie tussen genotype-spec-
ifieke verschillen in mitochondriële functie en de catecholamine concentraties in 
PPGL. Enzymatische assays van de ademhalingsketen en metabole studies 
middels 1H NMR spectroscopie bij 500 MH werden toegepast op homogenaten van 
35 sporadische PPGLs en 59 PPGLs van patiënten met erfelijke mutaties in SDHB, 
SDHD, SDHAF-2, VHL, RET, NF1 en MAX. In SDH-gerelateerde PPGLs werd een forse 
afname in complex II enzymatische activiteit waargenomen, terwijl de activiteit 
van complex I, III en IV hoger was ten opzichte van sporadische, VHL-, RET- en 
NF1-gerelateerde tumouren. Tevens was er een significante toename in de 
activiteit van het mitochondiële enzym citraat synthase in SDH-gerelateerde 
PPGLs ten opzicht van VHL-, RET- en NF1-gerelateerde tumouren. Dit ging gepaard 
met stapeling van de metaboliet succinaat en afname van  ATP/ADP/AMP en 
 catecholamineconcentraties in SDH-tumouren. Er werd een positieve correlatie 
gevonden tussen complex II activiteit enerzijds en ATP/ADP/AMP en catecholamine 
concentraties anderzijds. Dit is de eerste studie waarbij NMR spectroscopie met 
succes werd toegepast voor het meten van catecholamines in PPGL en waarbij het 
ex-vivo bewijs geleverd wordt voor de stapeling van succinaat in SDH-deficiënte 
tumouren.  
Het onderzoek beschreven in hoofdstuk 3 is een vervolg op de studie in hoofdstuk 2, 
waarbij de effecten van genetische mutaties op metabole netwerken in PPGL in 
detail worden bestudeerd. Hiervoor werden de homogenaten van 32 sporadische 
PPGLs en 48 PPGLs van patiënten met mutaties in SDHB, SDHD, SDHAF-2, VHL, RET 
en NF-1 onderzocht middels 1H NMR spectroscopie bij 500 MHz, ditmaal ten 
behoeve van ‘untargeted’ metabole profilering. Aanvullend werd gebruik gemaakt 
van LC tandem mass spectrometrie voor ‘targeted’ metabole profilering. Met 
1H NMR spectroscopie werden 28 metabolieten geïdentificeerd in PPGL waarvan 
er 12 genotype-specifieke verschillen lieten zien. Hierbij werden onder andere lage 
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NAA concentraties gevonden in SDHx-tumouren en lage creatine concentraties 
in VHL tumouren in vergelijking met sporadische tumouren en PPGLs met een 
ander genotype.
Er werd een positieve correlatie gevonden tussen NAA en ATP/ADP/AMP concentraties 
en tussen NAA en complex II activiteit. Targeted analyse van purine metabolieten 
toonde een lagere adenine concentratie in cluster 1 ten opzichte van cluster 2 
tumouren, terwijl juist lagere concentraties van guanosine en hypoxanthine 
werden gevonden bij RET tumouren ten opzichte van SDH tumouren. Het was 
mogelijk om met behulp van ‘principle component analysis’ van de metabole 
profielen PPGLs met verschillend genotypen van elkaar te onderscheiden.
Deze studie geeft een compleet overzicht van de veranderingen in energiemetab-
olisme bij SDH en VHL-gerelateerde PPGLs en geeft inzicht in de onderlinge relatie 
tussen energiemetabolisme, aminozuren en purine metabolieten in PPGL.
Bij het onderzoek in hoofdstuk 4 wordt de hypothese getest dat genotype- 
specifieke overexpressie van antisense HIF (aHIF) geassocieerd is met maligne 
kenmerken. Tumouren werden verzameld van 87 patiënten met PPGL. Quantitatieve 
PCR werd uitgevoerd voor aHIF, vascular endothelial growth factor (VEGF), 
aquaporin 3, cytochrome b561, p57Kip2, slit homolog 3 en SDHC. De expressie 
werd bestudeerd in relatie tot mutatiestatus, gemetastaseerde versus niet- 
gemetastaseerde tumouren en metastase-vrije overleving. We vonden dat zowel 
aHIF als VEGF een hogere expressie toont bij de cluster 1 tumouren en de maligne 
tumouren. Daarentegen was de expressie van slit homolog 3, p57Kip2, cytochrome 
b561, en SDHC juist hoger in niet-gemetastasseerde tumouren. Patiënten met 
tumouren met een hogere expressie van aHIF en VEGF hadden een verminderde 
metastase-vrije overleving. SDHC expressie correleerde juist met een toegenomen 
metastase-vrije overleving. Concluderend toont deze studie aan dat naast VEGF 
ook aHIF sterker tot expressie komt in cluster 1 PPG, hetgeen past in het bekende 
profiel van pseudohypoxie en angiogenese. Ook zijn aHIF en VEGF geassocieerd 
met een hogere kans op metastasering van PPGL.   
Het onderzoek dat wordt beschreven in hoofdstuk 5 betreft de hypothese dat 
toegenomen opname van 18F-FDG door SDH-gerelateerde PPGLs een teken is van 
toegenomen glycolytische activiteit en correleert met de expressie van eiwitten 
betrokken bij glucose opname en glycolyse. Bij patiënten met PPGL werden 
27 tumouren verzameld met de volgende genotypes: SDHB (n = 2), SDHD (n = 3), 
RET (n = 5), NF 1 en MAX (n = 1). 15 tumouren waren sporadisch. Pre-operatief 
werden 18F-FDG PET/CT scans verricht waarbij gemiddelde en maximum standard 
uptake values (SUVs) werden bepaald in de tumouren. De expressie in tumouren 
van eiwitten betrokken bij glucose uptake (GLUT-1 en -3), phosphorylering (HK-1, 
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-2, and -3), glycolyse (MCT-4) en angiogenese (VEGF, CD34) werd bepaald middels 
immuunhistochemische kleuring van paraffine-weefselcoupes. Deze expressie 
werd vergeleken met de corresponderende SUVs. Zoals verwacht waren de SUVs 
bij SDH-gerelateerde tumouren waren significant hoger dan bij sporadische 
tumouren en tumouren met een ander genotype. De expressie van HK-2 en HK-3 
was significant hoger in SDH-gerelateerde PPGLs dan in sporadische tumouren. 
De expressie van HK-2 en VEGF was significant hoger in SDH-gerelateerde PPGLs 
dan in PPGLs met andere genotypes. Er waren echter geen verschillen in de 
expressie van GLUT-1, GLUT-3 en MCT-4. Het percentage anti-CD 34 positieve cellen 
en de gemiddelde vaatperimeter waren hoger bij SDH-gerelateerde PPGLs dan bij 
sporadische tumouren. De gemiddelde SUVs correleerden met de expressie van 
HK-2, HK-3, VEGF en MCT-4. Daarom leidt activatie van aerobe glycolyse in SDH- 
gerelateerde PPGLs blijkbaar tot hogere  18F-FDG stapeling via een toename in 
phosphorylering in plaats van een toename in de expressie van glucosetransporters.
Hoofdstuk 6 bevat de discussie, waarbij de resultaten van het onderzoek in een 
breder perspectief worden geplaatst. Ook wordt de relevantie van de resultaten 
voor de (toekomstige) diagnostiek en behandeling van PPGL toegelicht. 
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